HIGHTIDE

君圣泰医药
HighTide Therapeutics, Inc.

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 2511

2025
INTERIM REPORT

CONTENTS

CORPORATE INFORMATION

EXECUTIVE DIRECTORS

Dr. LIU Liping (劉利平) *(Chairwoman of the Board and Chief Executive Officer of the Company)*
Ms. YU Meng (于萌)

NON-EXECUTIVE DIRECTORS

Dr. ZHU Xun (朱迅)
Mr. MA Lixiong (馬立雄) *(Deputy Chairman of the Board)*
Mr. JIANG Feng (江峰)

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. TAN Bo (譚擘)
Dr. LI Jin (李靖)
Mr. HUNG Tak Wai (孔德偉)

AUDIT COMMITTEE

Mr. TAN Bo (譚擘) *(Chairman)*
Dr. LI Jin (李靖)
Mr. HUNG Tak Wai (孔德偉)

REMUNERATION COMMITTEE

Dr. LI Jin (李靖) *(Chairman)*
Dr. LIU Liping (劉利平)
Mr. TAN Bo (譚擘)

NOMINATION COMMITTEE

Dr. LIU Liping (劉利平) *(Chairwoman)*
Dr. LI Jin (李靖)
Mr. HUNG Tak Wai (孔德偉)

JOINT COMPANY SECRETARIES

Ms. GAO Liping (高麗萍)
Ms. CHU Pik Man (朱璧敏)

AUTHORIZED REPRESENTATIVES

Dr. LIU Liping (劉利平)
Ms. CHU Pik Man (朱璧敏)

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Floor 9 to 10, Building D
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Fubao Community, Fubao Sub-district
Futian District, Shenzhen
Guangdong, PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40/F, Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong

REGISTERED OFFICE

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

AUDITOR

Moore CPA Limited
1001-1010, North Tower
World Finance Centre
Harbour City, 19 Canton Road
Tsim Sha Tsui, Kowloon
Hong Kong

LEGAL ADVISORS

As to Hong Kong law
Han Kun Law Offices LLP
Rooms 4301-10, 43/F
Gloucester Tower, The Landmark
15 Queen's Road Central
Hong Kong

As to Cayman Islands law
Conyers Dill & Pearman
29/F, One Exchange Square
8 Connaught Place Central
Hong Kong

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17/F
Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Conyers Trust Company (Cayman) Limited
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

PRINCIPAL BANKS

Citibank N.A. Hong Kong Branch
21/F, Citi Tower
One Bay East, 83 Hoi Bun Road
Kwun Tong, Kowloon
Hong Kong

Agricultural Bank of China Ltd., Hong Kong Branch
25/F., Agricultural Bank of China Tower
50 Connaught Road Central
Hong Kong

China Merchants Bank Shenzhen Branch
14th Floor
China Merchants Bank Shenzhen Branch Building
No. 2016 Shennan Avenue
Futian District
Shenzhen
PRC

STOCK CODE

2511

COMPANY'S WEBSITE

www.hightidetx.com

LISTING DATE

December 22, 2023

OVERVIEW

We are an innovative biopharmaceutical company specializing in the research and development of transformative therapeutic solutions for metabolic diseases. Our products deliver comprehensive benefits to patients worldwide.

Chronic metabolic diseases represent a significant unmet medical need and a tremendous burden for patients and caregivers worldwide. These diseases broadly share a pathogenic relationship that leads to the development of multiple metabolic comorbidities, complicating patient management and worsening prognosis. We are developing breakthrough therapies that simultaneously target the core disease as well as the comorbidities that increase a patient's risk, thus taking a holistic approach.

Our Core Product HTD1801 is a first-in-class new molecular entity (NME), addressing the residual risks of cardiovascular-kidney-metabolic (CKM) diseases. HTD1801 is an orally delivered, anti-inflammatory metabolic modulator and exhibits a unique dual mechanism of action – AMP kinase (AMPK) activation and NLRP3 inflammasome inhibition. AMPK activation enhances energy homeostasis and NLRP3 inhibition reduces systemic inflammation – both pathways working to mitigate dysfunctions associated with chronic metabolic and cardiovascular disease. Consistent with this dual mechanism of action, HighTide has robust clinical proof of concept data showing the multifunctional therapeutic effects of HTD1801, which exerts a broad range of metabolic benefits, including improved glycemic control, lipid-lowering (including atherogenic lipoproteins Lp(a), &ApoB), renal benefit, reduction in body weight, liver-specific benefits including lowering of ALT/AST, liver fat and fibrosis biomarkers, and markers of systemic inflammation including hs-CRP. Preclinical studies have further revealed HTD1801's potential in tumor prevention, anti-aging, and neuroprotection. We believe that HTD1801 has the potential to serve as a unique broad-spectrum metabolic regulator, capable of being used as a monotherapy or in combination with existing approved treatments for metabolic disorders, enabling optimal therapeutic outcomes and addressing patient needs.

HTD1801 is the only clinical-stage compound addressing residual risks in cardiovascular-kidney-metabolic (CKM) diseases through the dual mechanisms of AMPK activation and NLRP3 inflammasome inhibition. CKM syndrome is a complex health disorder made up of heart disease, kidney disease, and metabolic disorders such as diabetes and obesity. Despite major advances in the standard of care, significant residual risks remain in CKM-related diseases as the current therapies fall short of reversing the decrease of kidney function, effectively preventing the full control of metabolic issues, and addressing the full range of heart, kidney, and metabolic complications. With CKM-related diseases affecting nearly 90% of U.S. adults and 80% of Chinese adults, and given that nearly 590 million people are living with diabetes globally, the market for therapies targeting CKM syndrome is considerable yet underserved, creating a demand for innovative disease-modifying treatment. As CKM syndrome involves an interplay between chronic inflammation and metabolic dysregulation, through its dual mechanism, HTD1801 has strong therapeutic potential to address CKM-related diseases. HTD1801 has demonstrated clinical benefits on metabolic, renal, obesity, and cardiovascular complications. Therefore, we believe that HTD1801 has the potential to become a foundational CKM therapy.

The following diagram illustrates how HTD1801 may drive metabolic homeostasis through multiple mechanisms:



We are confident that our pipeline of innovative therapies positions us to seize opportunities in the rapidly growing global market for the treatment of significant metabolic diseases, which are expected to reach a market size of US$458 billion in 2032. With a focus on addressing metabolic and inflammatory comorbidities, our core strategy is to unlock the potential for indication expansion. HTD1801 is being developed globally to treat CKM syndrome-related disorders, including Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG). Along with HTD1801, we have developed a strong pipeline of similarly innovative product candidates comprising HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting ten potential indications collectively.

We have and are currently conducting multi-center clinical trials globally, including in the United States, China, Canada, and Australia, in a cost-effective and time-efficient manner, enabling us to leverage market opportunities worldwide. We have further developed a portfolio of intellectual property rights to protect our technologies and products on a global scale. As of the end of the Reporting Period, the Company has a total of 100+ patents and patent applications, with patent rights covering major countries and regions worldwide including the United States, Europe, Australia, New Zealand, Russia, Singapore and Japan. We believe that this expansive intellectual property portfolio creates an effective barrier to market entry and serves as a cornerstone for advancing our global commercialization objectives. With our lead product HTD1801 approaching commercialization in 2025, we are well-positioned to seize substantial market opportunities.

OUR PRODUCTS AND PRODUCT PIPELINE

As of the date of this report, we have researched and developed an in-house pipeline with 7 proprietary drug candidates covering 10 indications, including 2 compounds that are at the clinical stage for 7 different indications. The following chart summarizes the development status of our drug candidates as of the date of this report:

Candidate	Mechanism/Target	Indication	Right	Designations	Pre-Clinical	Phase I	Phase II	Phase III
HTD1801 ★	Dual Mechanisms AMPK Activation + NLRP3 Inflammasome Inhibition	T2DM	Global		Phase III trials are ongoing in Mainland China. NDA submission by 2025.			
		MASH	Global	FTD	Phase IIa trial completed in US; Phase IIb trial is ongoing in US, Mainland China and HK.			
		CKD	Global					
		Obesity	Global					
		PSC	Global	FTD, ODD	Phase II trial completed in US and Canada.			
		SHTG	Global				(1)	
HTD4010	Polypeptide Drug	AH	Global		Phase I trial completed in Australia.			
HTF1037	Mitochondria Uncoupler	Obesity	Global					
HTF1057	Mitochondria Uncoupler	Neurodegenerative Diseases	Global					
HTD1804	Undisclosed	Obesity	Global					
HTD1805	Undisclosed	Metabolic Disease	Global					
HTD2802	Undisclosed	IBD	Global					

★ Core Assets

Note: (1) We have completed a Phase Ib/IIa trial for hypercholesterolemia in Australia and a Phase IIa trial for MASH in the United States. Based on the FDA's written responses to the pre-investigational new drug meeting, the FDA concluded that the available preclinical and clinical data of the above trials was adequate to support the initiation of Phase II trial for SHTG.

HTD1801

- Our Core Product, HTD1801 is an orally delivered, first-in-class anti-inflammatory metabolic modulator being developed for the treatment of several CKM syndrome-related disorders, including T2DM, MASH, CKD, Obesity, PSC, and SHTG.

- As of the date of this report, HTD1801 has been granted two FTDs and one ODD from the FDA, and has been supported by the Major National Science and Technology Projects for "Major New Drugs Development" during the "Thirteenth Five-Year Plan" period in China. Benefiting from these favourable regulatory designations and programs, the global development programs for HTD1801 are advancing toward the commercialization stage, with late-stage clinical studies currently being conducted in China and the US. In China, multiple Phase III studies for T2DM have completed data readout in the first half of 2025, and an NDA submission for T2DM is expected by the end of 2025. In the United States, the Phase IIb study for MASH has completed patient enrollment and is also expected to be completed in 2025.

T2DM

- T2DM is one of the most common metabolic diseases worldwide. Chronic hyperglycemia along with the other metabolic aberrations (i.e., obesity, dyslipidemia, hypertension) in T2DM ultimately results in damage to various organ systems, leading to the development of life-threatening complications, primarily being microvascular and macrovascular complications which cause a 2-fold to 4-fold increased risk of cardiovascular diseases – major causes of death and disabilities and underscoring the need for comprehensive patient management. Therapy that addresses co-existing metabolic aberrations to deliver more comprehensive clinical benefit to patients remains an unmet need in the clinical management of T2DM.

- Our completed Phase Ib, Phase II and III clinical trials of T2DM in China have demonstrated a strong therapeutic effect of HTD1801 in improving glucose metabolism, including statistically significant decreases in hemoglobin A1c (HbA1c) and fasting glucose levels, which may be the result of decreased insulin resistance based on observed reductions in HOMA-IR with HTD1801. Collective results from our Phase Ib T2DM trial, Phase II T2DM trial, Phase III T2DM trial and Phase IIa MASH and T2DM trial suggest that HTD1801 has broad efficacy on glucose homeostasis, renal benefit, other cardiometabolic markers and liver health, supporting a differentiated profile compared to other anti-diabetic agents.

- At the American Diabetes Association's (ADA) 85th Scientific Sessions held in June 2025, we presented data from the Phase III SYMPHONY 1 trial highlighting the safety and efficacy of HTD1801 as monotherapy for T2DM. SYMPHONY 1 is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of HTD1801 as monotherapy compared to placebo in adults with T2DM with inadequate glycemic control despite dietary and exercise interventions. The primary endpoint in the study was the change in HbA1c from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Key messages from the presentation are as follows:

  – The study met its primary endpoint with a significant HbA1c reduction of -1.3%, and 42% of patients achieved target HbA1c levels <7%. Further, those with more severe disease had a greater decrease with HTD1801: reduction in HbA1c was -1.5% for those with a baseline HbA1c ≥8.5%. Improvements in HbA1c with HTD1801 were paralleled with significant improvements in postprandial and fasting plasma glucose compared with placebo.

  – In addition, HTD1801 demonstrated lipid-lowering effects, including significant reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C).

  – Moreover, HTD1801 treatment led to reductions in key inflammatory biomarkers – gamma-glutamyl transpeptidase (GGT) and high-sensitivity C-reactive protein (hs-CRP) – both of which are associated with cardiovascular risk in patients with T2DM, demonstrating the comprehensive benefits of HTD1801 monotherapy for the treatment of T2DM.

  – HTD1801 was found to be safe and generally well tolerated.

- At the European Association for the Study of the Liver (EASL) Congress 2025 held in May 2025, we presented the post-hoc analyses of a Phase II study evaluating the benefits of HTD1801 in patients with T2DM and presumed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key messages from the presentation are as follows:

  – HTD1801 treatment demonstrated dose-dependent improvements in both cardiometabolic and hepatic parameters in patients with T2DM and presumed MASLD, suggesting HTD1801 can comprehensively address metabolic and cardiovascular risk factors beyond glycemic control.

- In March 2025, we published data from a Phase II study evaluating the safety and efficacy of HTD1801 in patients with T2DM in JAMA Network Open. The randomized, placebo-controlled 12-week study demonstrated that HTD1801 was generally well-tolerated and delivered comprehensive therapeutic benefits with improvements in glycemic, anti-inflammatory, hepatic and cardiometabolic parameters. The multifaceted effects demonstrated by HTD1801 support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities.

- In addition to this primary publication, in 2024 the data from this trial was presented at global conferences.

- At the 60th European Association for the Study of Diabetes (EASD) Annual Meeting held in September 2024, two post-hoc analyses for the T2DM Phase II clinical study were presented, focusing on the efficacy of HTD1801 in Chinese and Western Patients with T2DM and the effects of HTD1801 response based on the degree of insulin resistance. Key messages from these EASD 2024 presentations are as follows:

  – HTD1801 improves glycemic, cardiometabolic, and hepatic outcomes in both Chinese and Western patients with T2DM and/or MASH. Despite ethnic differences and distinct disease presentations, HTD1801 provides holistic benefits that effectively address core aspects of both T2DM and MASH.

  – HTD1801 can alleviate the metabolic inhibitory effects caused by hyperinsulinemia, leading to even greater hepatic and metabolic benefits in patients with more severe insulin resistance, offering a unique therapeutic approach for individuals with T2DM and MASH.

- At the ADA 84th Scientific Session held in June 2024, a post-hoc analysis from the Phase II T2DM study presented the effectiveness of HTD1801 in patients with T2DM across the disease spectrum based on baseline HbA1c. Key messages from the presentation are as follows:

  – Regardless of baseline disease severity, HTD1801 treatment resulted in significant improvements in key glycemic and lipid metabolism markers, as well as indicators of liver injury with a greater improvement in subjects with more severe disease. Such data suggests HTD1801 may offer a unique therapeutic approach for individuals with T2DM and other comorbidities (i.e. MASH and dyslipidemia), as managing these conditions effectively is crucial in controlling T2DM and reducing its associated complications.

- The patient enrollments of the two Phase III registration trials of HTD1801 for the treatment of T2DM (SYMPHONY 1 and SYMPHONY 2) have been completed in June 2024.

- The patient enrollment of the dapagliflozin-controlled Phase III clinical trial of HTD1801 for the treatment of T2DM (HARMONY) was completed in January 2025. The head-to-head non-inferiority trial is a randomized, double-blind, active parallel-controlled (dapagliflozin), multicenter Phase III clinical trial designed to evaluate the efficacy of HTD1801 versus dapagliflozin in adult subjects with T2DM inadequately controlled with metformin alone. The primary efficacy endpoint is the change in HbA1c relative to baseline after 24 weeks of treatment.

- Two Phase III SYMPHONY trials (SYMPHONY 1 and SYMPHONY 2) of HTD1801 have met their primary endpoints, with the 24-week data readout completed in April 2025.

  The 52-week data readout from the two Phase III SYMPHONY trials is expected in the second half of 2025, and the HARMONY trial is also anticipated to have data readout in the second half of 2025.

- Based on these highly positive readouts, an NDA for HTD1801 as a treatment for T2DM is expected to be submitted by the end of 2025.

MASH

- Given the disease's pathogenetic complexity and heterogeneity, the treatment of MASH is trending toward a multifunctional therapeutic approach.

- We have completed a randomized, double-blind, placebo-controlled Phase IIa study of HTD1801 in patients with MASH and T2DM in the United States. The Phase IIa study met the primary endpoint, which showed that HTD1801 resulted in statistically significant, meaningful improvements in liver fat content, as assessed by MRI – PDFF, compared to a placebo. Throughout 2024 and as of the end of the Reporting Period, we presented Phase IIa results in global conferences.

- At the EASL Congress 2025 held in May 2025, we presented a post-hoc analysis of a Phase IIa study evaluating the effect of HTD1801 in patients with MASH and T2DM at a higher risk of disease progression and outcomes due to the presence of moderate to advanced fibrosis (defined as at-risk MASH). Key messages from the presentation are as follows:

  – Treatment with HTD1801 resulted in substantial improvements in key hepatic and cardiometabolic parameters in patients with at-risk MASH and compared to placebo, twice as many patients achieved a reduction in liver fat content (MRI-PDFF) or fibroinflammation (cT1) that have been associated with improvements in liver histology.

- At the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting held in November 2024, two post-hoc analyses for the MASH Phase IIa study were presented. These data provide additional characterization of the efficacy and safety of HTD1801, key messages from these AASLD 2024 presentations are as follows:

  – HTD1801 provides greater improvements in markers of liver injury and inflammation, glycemic control, weight loss, and lipid metabolism compared to ongoing GLP-1 receptor agonists (GLP-1RAs) use. HTD1801 could provide additional benefit to patients with MASH and T2DM, on concomitant GLP-1RAs treatment.

  – HTD1801 is generally well-tolerated, and with continued treatment, gastrointestinal (GI) tolerance improves, supporting its potential long-term use in chronic diseases.

- At the 8th Annual MASH Drug Development Summit taking place in September 2024, we made an oral presentation highlighting MASH and metabolic disease risk factors, along with preliminary metabolic and hepatic benefits observed in Phase IIa studies of HTD1801.

- At the EASL Congress in June 2024 multiple post-hoc analyses for the MASH Phase IIa study were presented including an evaluation of ongoing GLP-1RAs use compared to newly initiated HTD1801 treatment; analysis of the effects of HTD1801 response based on degree of insulin resistance; and a characterization of the time-course and severity of GI adverse events (AEs) after treatment with HTD1801. Key messages from the EASL 2024 presentations are as follows:

  – HTD1801 provides greater benefit across multiple cardiometabolic endpoints compared to ongoing GLP-1RAs use, and patients with MASH and T2DM, on concomitant GLP-1RAs, could achieve additional benefit in terms of further glucose and lipid lowering as well as weight loss with HTD1801.

  – Insulin resistance is a significant risk factor for T2DM, obesity and MASH. HTD1801 can alleviate the metabolic inhibitory effects caused by hyperinsulinemia, leading to even greater metabolic benefits in patients with MASH and more severe insulin resistance and therefore may offer a unique therapeutic approach for individuals with MASH and co-morbid T2DM.

  – With continued treatment with HTD1801, GI tolerability improves, supporting its potential for long-term use for the treatment of chronic disease, such as MASH.

- We are currently conducting a Phase IIb study of MASH. The study has been initiated in the United States, Hong Kong and Mainland China. The patient enrollment of Phase IIb has been completed. The data readout is expected to be conducted in 2025.

CKD

- CKD is a progressive condition characterized by the gradual loss of kidney function over time. The kidneys, which filter waste and excess fluids from the blood, become damaged and cannot perform their essential roles effectively, ultimately resulting in the need for renal replacement therapy, such as dialysis or transplantation.

- HTD1801 demonstrates strong therapeutic potential in CKD, including an improvement in the eGFR trajectory in the competitive landscape. In a 24-week study in patients with T2DM and mild renal impairment (baseline eGFR 60 – 89 mL/min/1.73m^2), treatment with HTD1801 resulted in a statistically significant improvement in eGFR. This was achieved with no observed changes in serum sodium or potassium levels, indicating electrolyte stability.

- Preclinical research further supports the renoprotective potential of HTD1801. Studies demonstrate that HTD1801 reduces serum creatinine and blood urea nitrogen levels, decreases urinary volume and microalbuminuria. Histological assessments also indicated attenuate kidney inflammation, and fibrosis, restoration of tubular and glomerular structure.

- Preclinical and clinical studies indicate that HTD1801 has the potential to modulate multiple pathogenic mechanisms related to kidney disease, offering an integrated intervention strategy for metabolic-related kidney diseases.

- Building on these findings, a Phase II clinical study of HTD1801 in patients with CKD is currently in preparation.

Obesity

- Obesity is a prevalent condition with a broad global market. Globally, over 1.9 billion adults are classified as overweight, with more than 650 million categorized as obese. Studies have shown that individuals with multiple metabolic abnormalities face an elevated risk of disease progression and mortality, and the increasing body mass index (BMI) is associated with a significantly greater risk of developing multiple morbidities related to obesity. Effective therapies for metabolic diseases, including obesity, should target the underlying metabolic comorbidities that contribute to disease pathogenesis and exacerbate outcomes.

- HTD1801 is positioned to address multiple metabolic disorders by targeting inflammation and metabolic dysregulation, and has demonstrated meaningful potential in weight management, with evidence supporting its role in reducing body weight while contributing to broader metabolic improvements. In the Phase IIa clinical trial of HTD1801 in patients with MASH and T2DM, an average weight loss of 3.5 kg was observed, with a greater reduction of 8 kg in patients with hyperinsulinemia.

- In preclinical studies, HTD1801 in combination with GLP-1RAs produced synergistic weight loss compared to GLP-1RAs monotherapy, while preserving lean mass.

- At the 3rd Obesity & Weight Loss Drug Development Summit held in US in July 2025, an oral presentation reported the weight loss efficacy of HTD1801. Key messages from the presentation are as follows:

  – By addressing both inflammation and metabolic dysfunction, HTD1801 has the potential to not only reduce body weight but also improve metabolic health, lower disease risk, and produce more durable, disease-modifying effects.

  – Enhanced weight reduction when HTD1801 is combined with GLP-1 RAs, while preserving lean mass – Improving the quality of weight loss.

  – Data supports the therapeutic potential of HTD1801 across multiple metabolic disease settings, including obesity.

- We are currently planning a Phase II clinical trial combining HTD1801 with a GLP-1RA for the treatment of obesity.

PSC

- PSC is a rare, chronic cholestatic liver disease characterized by intrahepatic and extrahepatic bile duct injury. Inflammation and fibrosis of the bile ducts lead to structural damage, impaired bile flow and progressive liver dysfunction. PSC has been identified by the European Association for the Study of the Liver as one of the largest unmet clinical needs in the category of liver disease. HTD1801 is precisely engineered to target the disease's complex pathogenic mechanisms through a multifunctional synergistic approach.

- HTD1801 provides a unique and comprehensive treatment of the gut-liver-biliary system, acting through multiple mechanisms to address the complex pathogenesis of PSC, including a choleretic effect achieved by displacing toxic bile acids from the bile acid pool and a variety of anti-inflammatory effects. In addition, HTD1801 treatment has demonstrated positive changes in the gut microbiome, an important contributor to the pathogenesis of PSC.

- We completed a Phase II clinical trial of HTD1801 for PSC in the United States and Canada in August 2020, with the HTD1801 treatment group demonstrating a statistically significant reduction in serum alkaline phosphatase, a key biomarker indicating the presence of cholestatic liver disease, compared to the placebo group. HTD1801 treatment was also associated with improvements in markers of liver injury and inflammation. In addition to its efficacy profile, HTD1801 demonstrated a good safety profile in this patient population, including liver-related safety. HTD1801 has been granted FTD and ODD from FDA for the treatment of PSC, which allows for expedited regulatory review. We had also held a successful end of Phase II (EOP2) meeting with FDA and were permitted to commence Phase III clinical trial.

SHTG

- SHTG is the presence of high levels of triglycerides (TGs), a type of fat, in the blood. SHTG is well known to be associated with other complex and serious disorders such as acute pancreatitis and Cardiovascular Diseases (CVDs). Existing pharmacological interventions primarily include the use of fibrates, omega-3 fatty acids, statins and niacin, but these treatment options either have limited efficacy or are associated with safety concerns. It is clear that there remains a medical need for safe and effective therapies for the treatment of adult patients with SHTG, therapies that address not only triglyceride levels but also comorbid conditions.

- For SHTG, preclinical studies demonstrated that HTD1801 could improve lipid metabolism in dyslipidemia and MASLD models. In addition, in a pooled analysis of clinical studies of MASH and hypercholesterolemia, focusing on subjects with baseline TGs above 200 mg/dL (hypertriglyceridemia), treatment with HTD1801 was associated with clinically meaningful reductions in TG levels, which supports the therapeutic potential of HTD1801 in SHTG.

- We have completed Phase I clinical trial in healthy subjects in Australia. We will continue to evaluate the clinical progress of HTD1801 and, taking into account the overall strategy and resources allocation of the Group, assess the timeframe of initiating the Phase II clinical trial of HTD1801 for the treatment of SHTG.

HTD4010

- Building on our expertise in the development of HTD1801, we have also invested in and developed our pipeline to cover Alcoholic Hepatitis (AH), Obesity, Inflammatory Bowel Disease (IBD) and other metabolic diseases to address large unmet medical needs of other patient populations. For the treatment of AH, we are advancing the early clinical development of HTD4010. AH is one of the manifestations of alcohol-associated liver disease characterized by acute liver inflammation.

- HTD4010 is a Phase I clinical-stage, polypeptide drug for the treatment of complex, life-threatening diseases such as AH, which is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. HTD4010 is a Toll-like receptor 4 inhibitor potentially capable of modulating the innate immune response and the resulting liver inflammation, a major contributor to AH pathogenesis. The Company has presented preclinical findings highlighting HTD4010's therapeutic potential at major international scientific conferences in 2025, including the EASL Congress and Digestive Disease Week (DDW).

- At the EASL Congress and DDW held in May 2025, we presented preclinical data for HTD4010. Key messages from two conferences' presentation are as follows:

  – Preclinical results for HTD4010 in an acute liver failure model revealed enhanced protective effects compared to DUR-928, suggesting its potential as a treatment for acute liver conditions, including alcohol-associated hepatitis.

  – Treatment with HTD4010 resulted in significant protective effects on acute pancreatitis. These findings provide evidence that HTD4010 may have a beneficial effect on acute pancreatitis and other acute-inflammatory-related conditions.

HTF1037

- HTF1037 is a preclinical-stage, potentially best-in-class mitochondrial uncoupler with a mechanism of elevating energy expenditure for the treatment of obesity and comorbidities as a monotherapy or combination with a GLP-1RA or other caloric restriction approach. In preclinical studies, HTF1037 demonstrated muscle sparing weight loss along with many other metabolic benefits, including improvement of liver health (reductions in liver total cholesterol and triglyceride, NAS, AST, ALT), deceased of fasting insulin/glucose levels, as well as reactive oxygen species (ROS). It also demonstrated type I muscle adaptation with muscle endurance functional improvement. In combination with Semaglutide, HTF1037 showed additive weight loss and reversed muscle loss due to Semaglutide monotherapy and suppressed weight rebound after cessation of treatment with Semaglutide. Preclinical safety evaluations suggested an acceptable margin of safety for projected human efficacious exposure.

HTF1057

- HTF1057 is a preclinical-stage mitochondria uncoupler being developed as a drug candidate for the treatment of neurodegenerative diseases. In preclinical studies, HTF1057 has demonstrated significant neuroprotection effects, including improvements in behavior deficits, rescuing neuron loss induced by toxin lesion, and suppressing in microglial cells and astrocytes activation. Additionally, HTF1057 increased brain derived neurotrophic factor (BDNF) levels. These findings support its potential as a therapeutic agent for Parkinson's Disease.

HTD1804

- An additional drug candidate, HTD1804, is under evaluation for the treatment of obesity, which is a growing global health risk associated with a wide range of comorbidities, most notably CVDs and T2DM.

- HTD1804 is a preclinical-stage, small molecule multifunctional therapy for the treatment of obesity. Preclinical studies have shown that HTD1804 may be an important modulator of energy metabolism to provide cardiovascular protection, and can effectively reduce the body weight of animals with obesity as well as lipid – and glucose-lowering effects.

HTD1805

- HTD1805, another drug candidate in our pipeline, is a preclinical-stage, multifunctional small molecule drug for the treatment of metabolic diseases. HTD1805 is prepared with the similar design rational as HTD1801, and the efficacy and safety profiles of the active moieties forming demonstrate the potential of HTD1805 in treating various metabolic diseases.

HTD2802

- HTD2802 is a preclinical-stage, multifunctional drug for the treatment of IBD, a common GI tract disorder. The existing IBD drugs fail to adequately control the symptoms and complications in many patients. In preclinical studies, HTD2802 has shown positive effects on improving stool formation, relieving abnormal weight loss and reducing the occurrence of fecal occult blood, as well as reducing inflammatory cytokine levels and preventing pathological injury.

Looking forward, we will continue to advance our pipeline of drug candidates through clinical development and continue to seek to expand the indication coverage of our pipeline. With respect to commercialization, based on the expected approval timeline of each indication of HTD1801 in our pipeline, we expect to file an NDA submission for HTD1801 for T2DM by the end of 2025. In anticipation of the upcoming milestone, we are actively seeking domestic partners with a strong commercialization network and expertise in T2DM. Subject to our global clinical development plan, we also plan to commercialize HTD1801 for T2DM, MASH, CKD, Obesity, PSC and SHTG in multiple jurisdictions, including but not limited to the United States, European Union and China.

THERE IS NO ASSURANCE THAT WE WILL BE ABLE TO ULTIMATELY DEVELOP AND MARKET ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY.

RESEARCH AND DEVELOPMENT CAPABILITY

We believe that our continued R&D is the key driver of our business growth and competitiveness.

Our R&D team has strong expertise, deep understanding, and broad development experience in metabolic diseases. Our R&D team is generally responsible for the global development of our pipeline products. For our internally discovered and developed drug candidates, we conducted drug discovery, quality assurance and clinical activities including: (i) coordinating all clinical development activities; (ii) designing the key aspects of the clinical studies; (iii) designing and coordinating the selection process for qualified CROs to assist in engaging clinical sites and coordinating clinical studies once commenced; (iv) supervising the clinical studies; and (v) overseeing extensive regulatory outreach and coordination in China and other jurisdictions. Our R&D team is led by a team of world-class scientists with years of drug development experience.

We have worked on our product candidates' advancement for more than ten years and developed product candidates in-house. Our drug discovery team members have expertise in biology, medicinal chemistry, drug metabolism and pharmacokinetics, chemistry and early clinical areas, which support our product development.

The clinical development team consisted of scientists and physicians with strong drug development experience, who participate in clinical development strategy development, clinical trial protocol design, clinical trial operation organization, drug safety monitoring, and clinical trial quality control. Our clinical development staffs represent a highly skilled and experienced team of professionals who work collaboratively to design and execute complex clinical trials and drug development programs. Our core capabilities in the area of development include clinical trial design, regulatory and quality compliance, project management, clinical operations, medical writing, safety monitoring and drug development strategy. Our team has the expertise to design clinical trials that are rigorous and compliant with regulatory requirements. This involves collaborating internally, with experts and regulatory authorities to determine the appropriate patient population, defining endpoints, and selecting appropriate control groups. The clinical development unit of our Company manages all stages of clinical trials, including protocol design and oversees, operations/conduct, and the collection and analysis of clinical data.

FINANCIAL OVERVIEW

The following discussion is based on, and should be read in conjunction with the financial information and notes included elsewhere in this report.

Other Income

Our other income decreased by RMB24.6 million from RMB35.1 million for the six months ended June 30, 2024 to RMB10.5 million for the six months ended June 30, 2025, representing a decrease of 70.1%. The decrease in other income was primarily because of a decrease of approximately RMB19.1 million in government grants.

Other Gains and Losses, Net

Our other gains and losses, net increased by RMB2.2 million from RMB3.0 million for the six months ended June 30, 2024 to RMB5.2 million for the six months ended June 30, 2025, which was primarily attributable to an increase in fair value gain on financial assets at FVTPL of approximately RMB5.7 million, partially offset by an increase in foreign exchange losses, net of approximately RMB3.6 million for the six months ended June 30, 2025.

Research and Development Costs

Our research and development costs primarily consist of (i) third-party contracting expenses primarily including early stage discovery expenses, preclinical expenses, and clinical development expenses for our drug candidates; (ii) staff costs, primarily consisting of salaries and benefits for our R&D team; (iii) expenses under the employee long-term incentive plans, representing expenses associated with share options granted to our R&D team; and (iv) others, primarily including rental, depreciation and amortization in relation to fixed assets, intangible assets, right-of-use assets and raw materials.

Our research and development costs decreased by 47.3% from RMB202.0 million for the six months ended June 30, 2024 to RMB106.4 million for the six months ended June 30, 2025. The decrease was mainly attributable to decreases of approximately RMB68.9 million in third-party contracting expenses and approximately RMB22.0 million in expenses under the employee long-term incentive plans.

The following table sets forth a breakdown of our research and development costs for the periods indicated:

	For the six months ended June 30,			
	2025		2024	
	RMB'000	***%***	*RMB'000*	*%*
Third-party contracting expenses	**77,420**	**73**	146,294	72
Staff costs	**16,140**	**15**	21,056	10
Expenses under the employee long-term incentive plans	**9,601**	**9**	31,560	16
Others	**3,253**	**3**	3,064	2
Total	**106,414**	**100**	201,974	100

Administrative Expenses

Our administrative expenses decreased by 53.0% from RMB46.1 million for the six months ended June 30, 2024 to RMB21.6 million for the six months ended June 30, 2025. The decrease in administrative expenses was primarily attributable to the decrease in expenses under the employee long-term incentive plans.

Loss for the Period

As a result of the above, we recorded a loss of RMB113.9 million for the six months ended June 30, 2025, as compared to a loss of RMB210.9 million for the six months ended June 30, 2024.

Capital Management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximize value to the Shareholders.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may return capital to the Shareholders or issue new Shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the Reporting Period.

Liquidity and Capital Resources

The Group has always adopted a prudent treasury management policy. The Group places strong emphasis on having funds readily available and accessible and is in a stable liquidity position with sufficient funds in standby banking facilities to cope with daily operations and meet its future development demands for capital.

As of June 30, 2025, the current assets of the Group were RMB506.2 million, of which long-term bank deposit matures within one year and cash and bank balances amounted to RMB236.9 million and other current assets amounted to RMB269.3 million. The Group's cash and bank balances decreased by 30.7% from RMB310.8 million as at December 31, 2024 to RMB215.5 million as at June 30, 2025. The decrease was mainly due to expenditure on research and development cost and administrative expenses. As at June 30, 2025, cash and bank balances were mainly denominated in United States dollars, Renminbi and Hong Kong dollars.

As of June 30, 2025, the current liabilities of the Group were RMB147.3 million, including interest-bearing bank borrowings of RMB80.3 million, trade payables of RMB54.8 million, other payables and accruals of RMB6.1 million and lease liabilities of RMB6.1 million.

Bank Borrowings

As of June 30, 2025, the Group had outstanding interest-bearing bank borrowings of approximately RMB80.3 million (December 31, 2024: RMB56.9 million) which were denominated in RMB and bearing interest on commercial bank borrowings at fixed annual interest rates ranging from 2.95% to 3.7%.

Charges on Group Assets

As of June 30, 2025, there were no charges on assets of the Company (December 31, 2024: nil).

Key Financial Ratios

The following table sets forth the key financial ratios for the dates indicated:

	As at June 30, 2025	As at December 31, 2024
Gearing Ratio [(1)]	**21.8%**	13.4%
Current Ratio [(2)]	**3.4**	4.7

Notes:

(1) Equals bank loans and other borrowings divided by total equity as of the same date.

(2) Equals current assets divided by current liabilities as of the same date.

Significant Investments

During the six months ended June 30, 2025, the Group held investments through two structured entities, Apollo Multi-Asset Growth Fund（"Apollo"）and Chaince Capital Fund LP ("Chaince") (together as the "**Funds**"), that the Group invested with initial investment costs of US$12.5 million each. Such investments were made before the Listing Date. As at December 31, 2024 and June 30, 2025, the Company held 12,375 shares in Apollo and the paid-in capital held by the Company in Chaince was USD12,375,000. As at June 30, 2025, the underlying assets purchased by Apollo and Chaince mainly included listed equity investments, treasury bills and money market funds, which were classified as financial assets at FVTPL of approximately RMB161.1 million and RMB68.9 million, respectively[Note]. Net unrealized fair value changes of losses of approximately RMB6.1 million and gains of approximately RMB5.8 million were recognized by us for the year ended December 31, 2024 and for the six months ended June 30, 2025, respectively. The listed equity investments are non-principal guaranteed with floating return. During the year ended December 31, 2024, the underlying assets purchased by Apollo and Chaince generated investment income of approximately RMB11.2 million and nil, respectively. During the six months ended June 30, 2025, the underlying assets purchased by Apollo and Chaince generated investment income of approximately RMB1.0 million and nil, respectively. No dividends were declared by the Funds during the year ended December 31, 2024 and the six months ended June 30, 2025.

Save as disclosed above, the Group did not have any significant investments and did not have other plans for significant investments or capital assets as at the date of this report.

With regards to significant investments, the Company has formulated prudent investment strategy of diversifying risks and generating steady returns on the premise of ensuring the safety of funds. The Company has ensured and will ensure that there remains sufficient working capital for its business needs, operating activities, research and development and capital expenditures after making the significant investments. The investment decisions were and will be made on a case-by-case basis and after due and careful consideration of a number of factors, such as the duration of the investment and the expected returns.

Note: Such fair values represent 30.5% and 13.0% of the Group's total assets as at June 30 2025, respectively.

Material Acquisitions and Disposals

The Group did not have any material acquisitions or disposals of subsidiaries, associates and joint ventures for the six months ended June 30, 2025.

Contingent Liabilities

The Group did not have any material contingent liabilities as at June 30, 2025.

Capital Commitments

As of December 31, 2024 and June 30, 2025, the Group did not have capital commitments contracted for but not yet provided.

Foreign Currency Risk

We have transactional currency exposures. Our Group's transactions were primarily denominated in US dollars, Renminbi and Hong Kong dollars. Certain of our cash and bank balances and trade and other payables are denominated in non-functional currency of the Company and exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, our management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Non-IFRS Measures

To supplement our consolidated statements of profit or loss which are presented in accordance with IFRS, we also use adjusted net loss as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. We believe that the presentation of non-IFRS measures when shown in conjunction with the corresponding IFRS measures provides useful information to investors and management in facilitating a comparison of our operating performance from period to period by eliminating potential impacts of certain non-operational expenses that do not affect our ongoing operating performance, including expenses under the employee long term incentive plans. Such non-IFRS measures allow investors to consider metrics used by our management in evaluating our performance. Expenses under the employee long-term incentive plans are non-operational expenses arising from granting options to selected directors, employees and consultants of the Company, the amount of which may not directly correlate with the underlying performance of our business operations, and is also affected by non-operating performance related factors that are not closely or directly related to our business activities. With respect to share awards, determining its fair value involves a high-degree of judgment. Historical occurrence of expenses under the employee long-term incentive plans is not indicative of any future occurrence. Therefore, we do not consider expenses under the employee long-term incentive plans to be indicative of our ongoing core operating performance and exclude them in reviewing our financial results. From time to time in the future, there may be other items that we may exclude in reviewing our financial results.

The use of the non-IFRS measures has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for or superior to analysis of, our results of operations or financial condition as reported under IFRS. In addition, the non-IFRS financial measures may be defined differently from similar terms used by other companies and therefore may not be comparable to similar measures presented by other companies.

The following table shows reconciliation of net loss for the period to our adjusted net loss for the periods indicated:

	For the six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
Net loss for the period	**(113,857)**	(210,945)
Added:		
Equity-settled share option arrangements	**13,122**	54,036
Adjusted net loss	**(100,735)**	(156,909)

Employees and Remuneration Policy

As at June 30, 2025, we had 57 employees in total. The following table sets forth the number of our employees categorized by function as of June 30, 2024 and June 30, 2025.

	Number of employees as at June 30, 2025	Number of employees as at June 30, 2024
Discovery and Clinical Development	**34**	42
Regulatory Affairs	**6**	6
Management Operations	**17**	20
Total	**57**	68

The total employee benefit expense (including Directors' and chief executive's remuneration) incurred by the Group was RMB34.9 million for the six months ended June 30, 2025 (six months ended June 30, 2024: RMB82.9 million). The decrease in remuneration cost was primarily attributable to the decrease in equity-settled share option expenses.

Our employees' remuneration comprises salaries, bonuses, provident funds, social security contributions, and other welfare payments. We have made contributions to our employees' social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds pursuant to applicable laws and regulations.

To maintain our workforce's quality, knowledge, and skill levels, we provide continuing education and training programs, including internal training, to improve their technical, professional or management skills. We also provide training programs to our employees from time to time to ensure their awareness and compliance with our policies and procedures in various aspects. Furthermore, we provide various incentives and benefits to our employees, including competitive salaries, bonuses and share-based payment, particularly our key employees.

The Company has adopted share incentive plans on January 22, 2020, May 24, 2023 and June 27, 2025, respectively. For further details, please refer to the paragraph headed "D. Incentive Plans" in Appendix IV to the Prospectus and the circular of the Company dated June 5, 2025.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the Corporate Governance Code as its own code of corporate governance. The Directors are of the view that throughout the Reporting Period, the Company has complied with all applicable code provisions of the Corporate Governance Code save and except for the following deviation from code provision C.2.1 of the Corporate Governance Code.

Under code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Dr. Liu has been serving as the chairwoman of the Board since the Listing and Chief Executive Officer since February 2018. With extensive experience in the pharmaceutical industry and having served in our Company since its establishment, Dr. Liu is in charge of overall strategic planning, business direction and operational management of our Group. Our Board considers that vesting the roles of chairwoman and chief executive officer in the same person is beneficial to the management of our Group. The balance of power and authority is ensured by the operation of our Board and our senior management, which comprises experienced and diverse individuals. Our Board currently comprises two executive Directors, three non-executive Directors and three independent non-executive Directors, and therefore has a strong independence element in its composition.

The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of chairperson and the chief executive officer is necessary.

COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Company's employees who, because of his/her office or employment, is likely to possess inside information in relation to the Company or its securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code throughout the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the employees of the Company who are likely to be in possession of inside information of the Company throughout the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities (including sale of treasury shares, as defined in the Listing Rules) during the Reporting Period. The Company did not hold any treasury shares (as defined in the Listing Rules) as of June 30, 2025.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration during the Reporting Period which could have a material and adverse effect on our financial condition or results of operations. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Company during the Reporting Period which could have a material and adverse effect on our financial condition or results of operations.

USE OF NET PROCEEDS FROM THE LISTING

The total net proceeds from the issue of shares by the Company in its Listing amounted to approximately HK$194.1 million, after deducting the underwriting commission and other expenses payable by the Company in connection with the Listing. During the Reporting Period, the net proceeds were used according to the intentions previously disclosed by the Company in the Prospectus. The balance of unutilized net proceeds amounted to approximately HK$92.6 million as at the end of the Reporting Period and the Company intends to use them in the same manner and proportions as described in the Prospectus and proposes to use the unutilized net proceeds in accordance with the expected timetable disclosed in the table below.

	Use of proceeds in the same manner and proportion as stated in the Prospectus *HK$ in million*	Net proceeds unutilized as at the beginning of the Reporting Period *HK$ in million*	Actual use of proceeds during the Reporting Period *HK$ in million*	Actual use of proceeds as at the end of the Reporting Period *HK$ in million*	Net proceeds unutilized as at the end of the Reporting Period *HK$ in million*	Expected time frame for utilizing the remaining unutilized net proceeds[Note]
Approximately 80.0% to fund the continuing clinical research and development activities of our HTD1801	155.2	95.3	26.5	86.4	68.8	December 2025
Approximately 5.0% to fund the ongoing research and development including R&D personnel costs and third party contracting expenses for HTD1804 for obesity	9.7	9.5	0.5	0.7	9.0	December 2025
Approximately 10.0% for the early drug discovery and development of other drug candidates from continuously upgrading and enhancing our FUSIONTX™ development approach	19.5	17.7	4.2	6.0	13.5	December 2025
Approximately 5.0% for working capital and other general corporate purposes	9.7	9.7	8.4	8.4	1.3	December 2025
Total	194.1	132.2	39.6	101.5	92.6	

Note: The expected timeframe for utilizing the remaining unutilized net proceeds is based on the best estimation of the factual business needs and future business development of the Group. It will be subject to change based on the current and future developments of market conditions and future business needs of the Group.

REVIEW OF INTERIM RESULTS

The Audit Committee, comprising three independent non-executive Directors, being Mr. TAN Bo (譚擘) (chairman of the Audit Committee with the appropriate professional qualifications), Dr. LI Jin (李靖) and Mr. HUNG Tak Wai (孔德偉), together with the management of the Company, have considered and reviewed this interim report, the Group's unaudited interim results for the Reporting Period, the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters, and are of the view that the interim results of the Group are prepared in compliance with the relevant accounting standards, laws and regulations and the Company has made appropriate disclosures thereof. The interim condensed consolidated financial information of the Group for the Reporting Period has not been audited. The Company's independent auditor, Moore CPA Limited, has performed an independent review of the Group's interim financial information for the Reporting Period in accordance with Hong Kong Standard on Review Engagements 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. There is no disagreement by the Audit Committee or the auditor of the Company with the accounting treatment adopted by the Company.

EVENTS AFTER THE REPORTING PERIOD

As announced by the Company on July 7, 2025, a total of 56,555,000 placing shares have been successfully placed by the placing agents to not less than six independent placees at the placing price of HK$2.21 per placing share pursuant to the terms and conditions of the placing agreement on July 7, 2025. The completion of the placing took place on July 7, 2025 in accordance with the terms of the placing agreement as set out in the announcement of the Company dated June 26, 2025. The aggregate net proceeds from the placing to be received by the Company (after deduction of the commissions and expenses relating to the placing) amounted to approximately HK$123.4 million. The Company intends to utilize the net proceeds from the placing for the clinical development and commercialization of HTD1801. For details, please refer to the announcements of the Company dated June 26, 2025 and July 7, 2025.

Save as disclosed above, there were no other important events affecting the Group occurred since June 30, 2025 and up to the date of this report.

INTERIM DIVIDEND

The Board did not recommend the distribution of an interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: nil).

CHANGES TO DIRECTORS' INFORMATION

Dr. ZHU Xun (朱迅), a non-executive Director, was appointed as an independent non-executive director of Medtide Inc. (泰德醫藥(浙江)股份有限公司), a company whose shares are listed on the Stock Exchange (stock code: 3880), with effect from June 30, 2025.

Save as disclosed above, since the date of the annual report of the Company for the year ended December 31, 2024 up to the date of this interim report, there has been no change to the information of the Directors which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

CONTINUING DISCLOSURE OBLIGATION PURSUANT TO THE LISTING RULES

Save as disclosed in this interim report, the Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY OF ITS ASSOCIATED CORPORATIONS

As at June 30, 2025, the interests or short positions of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of the Company or any associated corporations (within the meaning of Part XV of the SFO), which (a) were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she was taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein; or (c) were required to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

Interest in Shares and underlying Shares

Name of Director	Capacity/Nature of interest	Number of Shares held[1]	Approximate percentage of Shares in issue[2]
Dr. LIU Liping[6]	Founder of a discretionary trust[3]	81,000,000 (L)	15.74%
	Interest held through voting powers entrusted by other persons[4]	25,606,819 (L)	4.97%
	Beneficial interest[5]	10,004,964 (L)	1.94%
Mr. MA Lixiong	Interest in controlled corporation[7]	30,194,154 (L)	5.87%
	Beneficial interest[8]	5,926,584 (L)	1.15%
Ms. YU Meng	Beneficial interest[9]	6,032,568 (L)	1.17%
Dr. ZHU Xun	Beneficial interest[10]	1,336,908 (L)	0.26%

Notes:

(1) The letter "L" denotes the person's long position in the Shares.

(2) Based on a total of 514,770,668 Shares in issue as at June 30, 2025. On July 7, 2025, a total of 56,555,000 placing shares have been successfully placed by the placing agents to not less than six independent placees. For details, please refer to the announcements of the Company dated June 26, 2025 and July 7, 2025. This table does not take into account the effect of the subsequent placement after the Reporting Period.

(3) Dr. Liu, being the investment advisor of the Family Trust, is entitled to exercise the voting rights attached to the 81,000,000 Shares held by the Founder BVI.

(4) Comprising voting rights attached to 25,606,819 Shares underlying Awards vested which Dr. Liu was entitled to exercise the voting rights pursuant to the voting agreements entered into by the Company and certain grantees under the 2020 Share Incentive Plan and the 2023 Share Incentive Plan.

(5) As at June 30, 2025, Dr. Liu was interested in 10,004,964 shares underlying the Awards granted to her under the 2020 Share Incentive Plan, of which 7,457,872 Shares underlying the Awards were vested.

(6) Dr. Liu, the Founder BVI, Greaty Investment, ZT Global Energy and Orient Champion have entered into a concert party agreement (the "**Concert Party Agreement**") on September 30, 2021, pursuant to which the Founder BVI (the voting rights attached to the Shares held by whom are to be exercised by Dr. Liu), Greaty Investment, ZT Global Energy and Orient Champion confirmed and ratified that, since September 1, 2019, (i) they had acted and would continue to act in concert and collectively for all matters relating to the operation and development of our Group that need to be approved by the Shareholders pursuant to applicable laws and the constitutional documents of our Company; and (ii) when and if they could not reach unanimous consent, the decision of Dr. Liu shall prevail. None of the party to the Concert Party Agreement is entitled to terminate the Concert Party Agreement unilaterally. As of June 30, 2025, each of Greaty Investment, ZT Global Energy and Orient Champion held 6,369,372 Shares, 6,369,372 Shares and 5,616 Shares, each representing 1.24%, 1.24% and 0.00% of the issued Shares as at June 30, 2025.

(7) BAIYI Capital Limited is wholly-owned investment holding company of AIH Capital L.P., which is controlled by Mr. MA Lixiong. Pingtan Rongjing Investment Partnership (Limited Partnership) (平潭榮景投資合夥企業(有限合夥)) is managed by its general partner, Yuthai Investment Management Co., Ltd., which is owned as to 80% by Mr. MA Lixiong. Therefore, Mr. MA Lixiong is deemed to be interested in (i) 27,428,154 Shares held by BAIYI Capital Limited and (ii) 2,766,000 Shares held by Pingtan Rongjing Investment Partnership (Limited Partnership) under the SFO.

(8) As at June 30, 2025, Mr. MA Lixiong was interested in 5,926,584 Shares underlying the Awards granted to him under the 2020 Share Incentive Plan, and 2023 Share Incentive Plan, of which 2,741,190 Shares underlying the Awards were vested as at June 30, 2025.

(9) As at June 30, 2025, Ms. YU Meng was interested in 6,032,568 Shares underlying the Awards granted to her under the 2020 Share Incentive Plan, and 2023 Share Incentive Plan, of which 2,836,557 Shares underlying the Awards were vested as at June 30, 2025.

(10) As at June 30, 2025, Dr. ZHU Xun was interested 1,336,908 Shares underlying the Awards granted to him under the 2020 Share Incentive Plan, of which 1,190,832 Shares underlying the Awards were vested as at June 30, 2025.

Save as disclosed in this report and to the best knowledge of the Directors, as at June 30, 2025, none of the Directors or the chief executive of the Company has any interests and/or short positions in the Shares, underlying Shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

So far as the Directors or chief executive are aware, as at June 30, 2025, the following persons (other than the Directors and chief executive whose interests have been disclosed in this report), had an interest or short position in the Shares and underlying Shares which would fall to be disclosed to the Company pursuant to Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Name of Shareholder	Capacity/Nature of interest	Number of Shares held[1]	Approximate percentage of Shares in issue[2]
Mr. LI Li[3]	Interest in controlled corporation	77,804,710 (L)	15.11%
Ms. LI Tan[3]	Interest of spouse	77,804,710 (L)	15.11%
Hepalink[3]	Beneficial owner	13,515,210 (L)	2.63%
	Interest in controlled corporation	64,289,500 (L)	12.49%
Hepalink Biotechnology II Limited[3]	Beneficial owner	64,289,500 (L)	12.49%
Hepalink (Hong Kong) Limited[3]	Interest in controlled corporation	64,289,500 (L)	12.49%
Hepalink Healthcare Partners I L.P.[3]	Interest in controlled corporation	64,289,500 (L)	12.49%
Medi Prosperity Capital Inc.[3]	Interest in controlled corporation	64,289,500 (L)	12.49%
Shan Miao[3]	Interest in controlled corporation	64,289,500 (L)	12.49%
Founder BVI[4][5]	Beneficial owner	81,000,000 (L)	15.74%
The Bryn Mawr Trust Company of Delaware[4]	Trustee of a trust	81,000,000 (L)	15.74%
2020 ESOP Platform[6]	Beneficial owner	53,083,764 (L)	10.31%
The Core Trust Company Limited[6]	Trustee of a trust	53,083,764 (L)	10.31%
TCT (BVI) Limited[6]	Interest in controlled corporation	53,083,764 (L)	10.31%
Hongtu Capital[7]	Beneficial owner	45,713,592 (L)	8.88%
Ms. CHAN See Ting[7]	Interest in controlled corporation	45,713,592 (L)	8.88%
Mr. LAI Hoi Man[7]	Interest in controlled corporation	45,713,592 (L)	8.88%
BAIYI Capital Limited	Beneficial owner	27,428,154 (L)	5.33%

Notes:

(1) The letter "L" denotes the person's long position in the Shares.

(2) Based on a total of 514,770,668 Shares in issue as at June 30, 2025. On July 7, 2025, a total of 56,555,000 placing shares have been successfully placed by the placing agents to not less than six independent placees. For details, please refer to the announcements of the Company dated June 26, 2025 and July 7, 2025. This table does not take into account the effect of the subsequent placement after the Reporting Period.

(3) Based on the information set out in the relevant disclosure made by the relevant substantial Shareholder(s), 64,289,500 Shares were held by Hepalink Biotechnology II Limited, which was wholly-owned by Hepalink Healthcare Partners I L.P., a limited partnership established under the laws of the Cayman Islands. The limited partner of Hepalink Healthcare Partners I L.P. was Hepalink (Hong Kong) Limited, which held 100% of the interest in Hepalink Healthcare Partners I L.P. Hepalink (Hong Kong) Limited was in turn wholly-owned by Hepalink. Mr. LI Li was interested in approximately 62.90% of the shares in Hepalink. Hepalink was also interested in 13,515,210 Shares. Ms. LI Tan is the spouse of Mr. LI Li. Medi Prosperity Capital Inc., which is wholly-owned by Mr. Shan Miao, is the general partner of Hepalink Healthcare Partners I L.P. Therefore, Medi Prosperity Capital Inc. and Mr. Shan Miao are deemed to be interested in the shares held by Hepalink Healthcare Partners I L.P.

(4) The Bryn Mawr Trust Company of Delaware serves as the trustee of the Family Trust, which wholly-owned the Founder BVI.

(5) Dr. Liu, the Founder BVI, Greaty Investment, ZT Global Energy and Orient Champion have entered into the Concert Party Agreement on September 30, 2021, pursuant to which the Founder BVI (the voting rights attached to the Shares held by whom are to be exercised by Dr. Liu), Greaty Investment, ZT Global Energy and Orient Champion confirmed and ratified that, since September 1, 2019, (i) they had acted and would continue to act in concert and collectively for all matters relating to the operation and development of our Group that need to be approved by the Shareholders pursuant to applicable laws and the constitutional documents of our Company; and (ii) when and if they could not reach unanimous consent, the decision of Dr. Liu shall prevail. None of the party to the Concert Party Agreement is entitled to terminate the Concert Party Agreement unilaterally. As of June 30, 2025, each of Greaty Investment, ZT Global Energy and Orient Champion held 6,369,372 Shares, 6,369,372 Shares and 5,616 Shares, each representing 1.24%, 1.24% and 0.00% of the issued Shares as at June 30, 2025.

(6) The Core Trust Company Limited serves as the trustee of the 2020 ESOP Platform. The 2020 ESOP Platform is wholly-owned by TCT (BVI) Limited, which is in turn wholly-owned by The Core Trust Company Limited.

(7) Based on the information set out in the relevant disclosure made by the relevant substantial Shareholder(s), Hongtu Capital is owned as to 60% and 40% by Mr. LAI Hoi Man (賴海民) and Ms. CHAN See Ting (陳思廷), respectively,

Save as disclosed above, so far as the Directors or chief executive are aware, as at June 30, 2025, no person, other than the Directors and chief executive whose interests are set out in the section headed "Directors' and Chief Executive's Interests and Short Positions in Shares and Underlying Shares and Debentures of the Company or any of its Associated Corporations" had an interest or short position in the Shares or underlying Shares which would fall to be recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

INCENTIVE PLANS ADOPTED BY THE COMPANY

A. 2020 Share Incentive Plan

The 2020 Share Incentive Plan was originally adopted by the Board on January 22, 2020, amended and restated by the Board on October 18, 2021 and further amended and restated in its entirety on March 4, 2022. The terms of the 2020 Share Incentive Plan are not subject to the provisions of Chapter 17 of the Listing Rules as it does not involve any grant of awards by our Company to subscribe for new Shares after the Listing. After Listing, no further awards or other type of awards would be granted pursuant to the 2020 Share Incentive Plan. All the Shares underlying the Awards granted under the 2020 Share Incentive Plan have been issued and allotted to the 2020 ESOP Platform for future exercise of the Awards. The following is a summary of the principal terms of the 2020 Share Incentive Plan.

(a) Purpose

The purpose of the 2020 Share Incentive Plan is to enable the Company to attract and retain the best available personnel, to provide additional incentives to employees, Directors and consultants and to promote the success of the Company's business.

(b) Who May Join

Eligible participants (the "**Eligible Participants**") means (i) any person who is in the employment of the Group; (ii) a member of the Board or the board of directors of any affiliate of the Company; or (iii) any person who is engaged by the Group to render consulting or advisory services.

Subject to above classes, share options (the "**Options**") or restricted share units (the "**RSUs**") shall be granted to the grantee who is department manager, key technical staff of the Group; has made a significant contribution to the Company; or meet such other conditions as determined by Board, and restricted shares (the "**Restricted Shares**", together with the Options and the RSUs, the "**Awards**") or RSUs shall be granted to the grantee who is management personnel and has established labor/employment relationship with the Company or its subsidiaries before December 31, 2015 and the continuous service of the grantee is not terminated up to the date of the Award agreement; has made a significant contribution to the Company; is critical to the future development of the Company; or meet such other conditions as determined by Board.

(c) Shares Available for Issue

As of the date of this report, there is no Share available for issue under the 2020 Share Incentive Plan, as all the Shares underlying the Awards granted under the 2020 Share Incentive Plan have been issued and allotted to the 2020 ESOP Platform for future exercise of the Awards and no further options or other type of awards would be granted pursuant to the 2020 Share Incentive Plan after the Listing. The number of options and awards available for grant under the 2020 Share Incentive Plan as of the January 1, 2025 and June 30, 2025 was nil and nil, respectively.

(d) Maximum Number of Shares

The maximum number of Shares in respect of which Awards may be granted under the 2020 Share Incentive Plan is 53,095,764 Shares (as adjusted upon completion of the capitalization issue on the Listing Date and the repurchase of Shares from the 2023 ESOP Platform) (the "**2020 Scheme Limit**").

Any Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the 2020 Share Incentive Plan. Shares that actually have been issued under the 2020 Share Incentive Plan pursuant to an Award shall not be returned to the 2020 Share Incentive Plan and shall not become available for future issuance under the 2020 Share Incentive Plan, subject to the 2020 Share Incentive Plan. There is no service provider sub-limit adopted under the 2020 Share Incentive Plan. Subject to the 2020 Scheme Limit, the 2020 Share Incentive Plan contains no provision on the maximum entitlement of each Eligible Participant.

(e) Exercise Period

The exercise period of the Awards granted under the 2020 Share Incentive Plan is ten years commencing from the date upon which the Awards are deemed to be granted and accepted pursuant to the terms of the 2020 Share Incentive Plan.

(f) Vesting Period

The Awards granted under the 2020 Share Incentive Plan shall vest in four years subject to the Listing. The Awards representing 25% of the Awards granted shall vest in equal, yearly installments at each anniversary date commencing from the vesting commencement date set forth in the notice of Award and the Award agreements. The vesting of the Awards is also subject to other vesting conditions, including the Grantee's provision of continuous service to the Company or its affiliates and the performance criteria to be satisfied by each of the Grantees set forth in their respective notice of Award and Award agreements. The performance criteria comprise a mixture of attaining satisfactory key performance indicators of the Company, the department of the Company and the individual Grantee, respectively.

(g) Exercise or Purchase Price

The exercise price of the Options and the purchase price of the RSUs shall be the price determined by the administrator as of the date of grant. There is no purchase price for the Restricted Shares. Subject to applicable laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including the method of payment, shall be determined by the administrator.

The outstanding Awards granted under the 2020 Share Incentive Plan were granted at nil consideration to each of the relevant Eligible Participant with an exercise price (as adjusted by the capitalization issue on the Listing Date) of US$0.14 to US$0.47 per Share. There is no additional amount payable on application or acceptance of the Awards. There is no prescribed period within which payments or calls must or may be made or loans for such purposes must be repaid in respect of the Awards offered under the 2020 Share Incentive Plan.

(h) Term of Plan and Remaining Life

The 2020 Share Incentive Plan shall continue in effect for a term of ten (10) years after the date of adoption (being January 22, 2020), unless sooner terminated. The remaining life of the 2020 Share Incentive Plan was approximately four years and four months as of the date of this report.

All the Awards available for granting under the 2020 Share Incentive Plan have been granted before the Listing and there are no further options or other type of awards available for grant pursuant to the 2020 Share Incentive Plan since the Listing. As at June 30, 2025, no other types of awards other than options had been granted under the 2020 Share Incentive Plan. Therefore, there is no award granted during the Reporting Period. During the Reporting Period, details of the movements in the Awards (all being Options) granted under the 2020 Share Incentive Plan are as follows.

Name of category of grantee	Date of grant[1]	Number of Shares underlying the relevant Options: Outstanding Options as at January 1, 2025	Vested during the Reporting Period	Exercised during the Reporting Period[2]	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Expired during the Reporting Period	Outstanding Options as at June 30, 2025	Vesting period	Exercise period of Options	Exercise price of Options (approximate)[3]
											(US$ per Share)
Directors											
Dr. LIU Liping (劉利平)	December 17, 2020,	3,273,852	Nil	Nil	Nil	Nil	Nil	3,273,852	Four years[4]	Ten years[5]	0.14
	December 30, 2021,	1,636,926	409,231	Nil	Nil	Nil	Nil	1,636,926	Four years[4]	Ten years[5]	0.18
	April 1, 2023	5,094,186	1,273,547	Nil	Nil	Nil	Nil	5,094,186	Four years[4]	Ten years[5]	0.47
Ms. YU Meng (于萌)	January 1, 2021	1,681,092	420,273	Nil	Nil	Nil	Nil	1,681,092	Four years[4]	Ten years[5]	0.18
	April 1, 2023	1,951,476	487,869	Nil	Nil	Nil	Nil	1,951,476	Four years[4]	Ten years[5]	0.33
Dr. ZHU Xun (朱迅)	January 1, 2021	1,044,756	261,189	Nil	Nil	Nil	Nil	1,044,756	Four years[4]	Ten years[5]	0.18
	April 1, 2023	292,152	73,038	Nil	Nil	Nil	Nil	292,152	Four years[4]	Ten years[5]	0.33
Mr. MA Lixiong (馬立雄)	December 30, 2021	431,592	Nil	Nil	Nil	Nil	Nil	431,592	Four years[4]	Ten years[5]	0.18
	April 1, 2023	3,094,992	773,748	Nil	Nil	Nil	Nil	3,094,992	Four years[4]	Ten years[5]	0.33
Subtotal		18,501,024	3,698,895	Nil	Nil	Nil	Nil	18,501,024			

Name of category of grantee	Date of grant[1]	Number of Shares underlying the relevant Options: Outstanding Options as at January 1, 2025	Vested during the Reporting Period	Exercised during the Reporting Period[2]	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Expired during the Reporting Period	Outstanding Options as at June 30, 2025	Vesting period	Exercise period of Options	Exercise price of Options (approximate)[3]
											(US$ per Share)
Highest paid individuals during the Reporting Period excluding three Directors, in aggregate[6]											
	January 1, 2021	4,572,528	1,143,132	Nil	Nil	Nil	Nil	4,572,528	Four years[4]	Ten years[5]	0.18
	February 1, 2021	1,440,000	360,000	Nil	Nil	Nil	Nil	1,440,000	N/A	Ten years[5]	0.18
	April 1, 2023	3,683,292	920,824	Nil	Nil	Nil	Nil	3,683,292	Four years[4]	Ten years[5]	0.33/0.47
	September 1, 2023	5,821,050	Nil	Nil	Nil	Nil	Nil	5,821,050	Four years[4]	Ten years[5]	0.33
Subtotal		15,516,870	2,423,956	Nil	Nil	Nil	Nil	15,516,870			
Other grantees, in aggregate											
	December 17, 2020	543,912	Nil	Nil	Nil	Nil	Nil	543,912	Four years[4]	Ten years[5]	0.14
	January 1, 2021	4,186,202	Nil	Nil	Nil	Nil	Nil	4,186,202	Four years[4]	Ten years[5]	0.14
	March 1, 2021	388,650	97,162	Nil	Nil	Nil	Nil	388,650	Four years[4]	Ten years[5]	0.14
	December 30, 2021	421,614	Nil	Nil	Nil	140,538	Nil	281,076	Four years[4]	Ten years[5]	0.18
	January 3, 2022	210,252	Nil	Nil	Nil	210,252	Nil	Nil	Four years[4]	Ten years[5]	0.29
	January 3, 2022	360,000	Nil	Nil	Nil	360,000	Nil	Nil	Upon the achievement of applicable milestones[4]	Ten years[5]	0.29
	March 31, 2022	54,000	13,500	Nil	Nil	Nil	Nil	54,000	Four years[4]	Ten years[5]	0.29
	April 1, 2023	6,137,622	923,969	Nil	Nil	2,739,630	Nil	3,397,992	Four years[4]	Ten years[5]	0.33 – 0.47
	September 1, 2023	715,920	Nil	Nil	Nil	203,730	Nil	512,190	Four years[4]	Ten years[5]	0.33
Subtotal		13,018,172	1,034,631	Nil	Nil	3,654,150	Nil	9,364,022			
Total		**47,036,066**	**7,157,482**	**Nil**	**Nil**	**3,654,150**	**Nil**	**43,381,916**			

Notes:

(1) The fair value of the Options granted during the Reporting Period under Rule 17.07(1)(c)(v) of the Listing Rules is not applicable as no Option was granted during the Reporting Period.

(2) The weighted average closing price of the Shares immediately before the date on which the Options were exercised under Rule 17.07(1)(d) of the Listing Rules is not applicable as no Option was exercised during the Reporting Period.

(3) The exercise price has been adjusted by the capitalization issue on the Listing Date.

(4) The Awards shall vest in four years subject to the Listing. The Awards representing 25% of the Awards granted shall vest in equal, yearly installments at each anniversary date commencing from the vesting commencement date set forth in the notice of Award and the Award agreements. The vesting of the Awards that become ready to be vested according to their respective designated vesting schedule in the notice of Award on a date prior to the Listing will be deferred and only effected on the Listing Date. The vesting of the Awards is also subject to other vesting conditions, including the Grantee's provision of continuous service to the Company or its affiliates and the performance criteria to be satisfied by each of the Grantees set forth in their respective notice of Award and Award agreements. The performance criteria comprise a mixture of attaining satisfactory key performance indicators of the Company, the department of the Company and the individual Grantee, respectively.

(5) The exercise period of the Awards granted under the 2020 Share Incentive Plan is ten years commencing from the date upon which the Awards are deemed to be granted and accepted pursuant to the terms of the 2020 Share Incentive Plan.

(6) Excludes Dr. Liu Liping and Ms. Yu Meng, who were among the five top-paid individuals during the Reporting Period, and whose interest in the Options are disclosed separately in the table.

(7) Save for those set out in this movement table, there are no grants of awards to (i) Directors, (ii) five highest paid individuals during the Reporting Period, or (iii) other grantees under the 2020 Share Incentive Plan.

B. 2023 Share Incentive Plan

The 2023 Share Incentive Plan was adopted by the Board on May 24, 2023. The terms of the 2023 Share Incentive Plan are not subject to the provisions of Chapter 17 of the Listing Rules as it does not involve any grant of awards by our Company to subscribe for new Shares after Listing. After the Listing, no further awards would be granted pursuant to this 2023 Share Incentive Plan. All the Shares underlying the Awards granted under the 2023 Share Incentive Plan have been issued and allotted to the 2023 ESOP Platform for future exercise of the Awards. The following is a summary of the principal terms of the 2023 Share Incentive Plan.

(a) Purpose

The purpose of the 2023 Share Incentive Plan is to enable the Company to attract and retain the best available personnel, to provide additional incentives to employees, Directors and consultants and to promote the success of the Company's business.

(b) Who May Join

Eligible participants means any person belonging to (i) any person who is in the employment of the Group; (ii) a member of the Board or the board of directors of any affiliate of the Company; or (iii) any person who is engaged by the Group to render consulting or advisory services.

Subject to above classes, Options or RSUs shall be granted to the grantee who is department manager, key technical staff of the Group; has made a significant contribution to the Company; or meet such other conditions as determined by Board.

Restricted Shares, together with the Awards or RSUs shall be granted to the grantee who is management personnel, department manager, key technical staff that has established employment or consulting relationship with the Company or its Subsidiaries; and has made a significant contribution in furtherance of the purposes of this Plan; or meet such other conditions as determined by the Administrator.

(c) Shares Available for Issue

As of the date of this report, there is no Share available for issue under the 2023 Share Incentive Plan, as all the Shares underlying the Awards under the 2023 Share Incentive Plan have been issued and allotted to the 2023 ESOP Platform and no further options or other type of awards would be granted pursuant to the 2023 Share Incentive Plan after the Listing. The number of options and awards available for grant under the 2023 Share Incentive Plan as of January 1, 2025 and June 30, 2025 was nil and nil, respectively.

(d) Maximum Number of Shares

The maximum number of Shares in respect of which Awards may be granted under the 2023 Share Incentive Plan is 9,600,000 Shares (as adjusted upon completion of the capitalization issue on the Listing Date and the repurchase of Shares from the 2023 ESOP Platform) (the "**2023 Scheme Limit**").

Any Shares covered by an Award (or portion of an Award) which is forfeited, canceled or expires (whether voluntarily or involuntarily) shall be deemed not to have been issued for purposes of determining the maximum aggregate number of Shares which may be issued under the 2023 Share Incentive Plan. Shares that actually have been issued under the 2023 Share Incentive Plan pursuant to an Award shall not be returned to the 2023 Share Incentive Plan and shall not become available for future issuance under the 2023 Share Incentive Plan, subject to the 2023 Share Incentive Plan. There is no service provider sub-limit adopted under the 2023 Share Incentive Plan. Subject to the 2023 Scheme Limit, the 2023 Share Incentive Plan contains no provision on the maximum entitlement of each Eligible Participant.

(e) Exercise Period

The exercise period of the Awards granted is ten years commencing from the date upon which the Awards are deemed to be granted and accepted pursuant to the terms of the 2023 Share Incentive Plan.

(f) Vesting Period

The Awards representing 25% of the Awards granted shall vest in equal, yearly installments at each of the first anniversary date, the second anniversary date, the third anniversary date and the fourth anniversary date commencing from the Listing Date. The vesting of the Awards is also subject to other vesting conditions, including the Grantee's provision of continuous service to the Company or its affiliates and the performance criteria to be satisfied by each of the Grantees set forth in their respective notice of Award and Award agreements. The performance criteria comprise a mixture of attaining satisfactory key performance indicators of the Company, the department of the Company and the individual Grantee, respectively.

(g) Exercise or Purchase Price

The exercise price of the Options and the purchase price of the RSUs shall be the price determined by the administrator as of the date of grant. There is no purchase price for the Restricted Shares. Subject to applicable laws, the consideration to be paid for the Shares to be issued upon exercise or purchase of an Award including the method of payment, shall be determined by the administrator.

The outstanding Awards granted under the 2023 Share Incentive Plan were granted at nil consideration to each of the relevant Eligible Participant with an exercise price (as adjusted by the capitalization issue on the Listing Date) of US$0.33 per Share. There is no additional amount payable on application or acceptance of the Awards. There is no prescribed period within which payments or calls must or may be made or loans for such purposes must be repaid in respect of the Awards offered under the 2023 Share Incentive Plan.

(h) Term of Plan and Remaining life

The 2023 Share Incentive Plan shall continue in effect after the date of adoption, until the earlier to occur: (i) early termination by the administrator; or (ii) the tenth anniversary after the effective date (being May 24, 2023). The remaining life of the 2023 Share Incentive Plan was approximately seven years and eight months as of the date of this report.

All the Awards available for granting under the 2023 Share Incentive Plan have been granted before the Listing and there are no further options or other type of awards available for grant pursuant to the 2023 Share Incentive Plan since the Listing. As at June 30, 2025, no other types of awards other than options had been granted under the 2023 Share Incentive Plan. Therefore, there is no award granted from the Reporting Period. During the Reporting Period, details of the movements in the Awards (all being Options) granted under the 2023 Share Incentive Plan are as follows.

Name of category of grantee	Date of grant[1]	Outstanding Options as at January 1, 2025	Vested during the Reporting Period	Exercised during the Reporting Period[2]	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Expired during the Reporting Period	Outstanding Options as at June 30, 2025	Fair value of the Options (granted during the Reporting Period) at the date of grant (US$ per Share)	Vesting period	Exercise period of Options	Exercise price of Options (approximate)[5] (US$ per Share)
Directors												
Ms. YU Meng (于萌)	September 1, 2023	2,400,000	600,000	Nil	Nil	Nil	Nil	2,400,000	Nil	Four years[3]	Ten years[4]	0.33
Mr. MA Lixiong (馬立雄)	September 1, 2023	2,400,000	600,000	Nil	Nil	Nil	Nil	2,400,000	Nil	Four years[3]	Ten years[4]	0.33
Subtotal		4,800,000	1,200,000	Nil	Nil	Nil	Nil	4,800,000				
Other grantees, in aggregate												
	September 1, 2023	4,800,000	600,000	Nil	2,400,000	Nil	Nil	2,400,000	Nil	Four years[3]	Ten years[4]	0.33
Subtotal		4,800,000	600,000	Nil	2,400,000	Nil	Nil	2,400,000				
Total		**9,600,000**	**1,800,000**	**Nil**	2,400,000	**Nil**	**Nil**	**7,200,000**				

Notes:

(1) The fair value of the Options granted during the Reporting Period under Rule 17.07(1)(c)(v) of the Listing Rules is not applicable as no Option was granted during the Reporting Period.

(2) The weighted average closing price of the Shares immediately before the date on which the Options were exercised under Rule 17.07(1)(d) of the Listing Rules is not applicable as no Option was exercised during the Reporting Period.

(3) The Awards representing 25% of the Awards granted shall vest in equal, yearly installments at each of the first anniversary date, the second anniversary date, the third anniversary date and the fourth anniversary date commencing from the Listing Date. The vesting of the Awards is also subject to other vesting conditions, including the Grantee's provision of continuous service to the Company or its affiliates and the performance criteria to be satisfied by each of the Grantees set forth in their respective notice of Award and Award agreements. The performance criteria comprise a mixture of attaining satisfactory key performance indicators of the Company, the department of the Company and the individual Grantee, respectively.

(4) The exercise period of the Awards granted under the 2023 Share Incentive Plan is ten years commencing from the date upon which the Awards are deemed to be granted and accepted pursuant to the terms of the 2023 Share Incentive Plan.

(5) The exercise price has been adjusted by the capitalization issue on the Listing Date.

(6) Save for those set out in this movement table, there are no grants of awards to (i) Directors, (ii) five highest paid individuals during the Reporting Period or (iii) other grantees under the 2023 Share Incentive Plan.

(7) The Remuneration Committee was established with effect from the Listing Date, while all the grants under the 2023 Share Incentive Plan were made before the Listing Date. As such, no grant was made under the 2023 Share Incentive Plan which requires review by the Remuneration Committee for the Reporting Period.

(8) As all grants under the 2023 Share Incentive Plan were made before the Listing Date, the closing price of the shares immediately before the date of grant under Rule 17.07(1)(c)(iv) of the Listing Rules is not applicable.

C. 2025 Share Incentive Plan

The Company adopted the 2025 Share Incentive Plan pursuant to an ordinary resolution passed by the Shareholders in the annual general meeting held on June 27, 2025 ("**Adoption Date**"). The 2025 Share Incentive Plan will be funded by the existing Shares underlying the awards granted before the Listing but then subsequently lapsed or canceled from time to time under the Pre-IPO Share Incentive Plans and no new Shares/treasury shares will be issued/transferred by the Company. As the Shares lapsed or canceled under the Pre-IPO Share Incentive Plans are now held/will be held by the trustees for no specific participants upon the awards being lapsed or canceled pursuant to the terms of the Pre-IPO Share Incentive Plans, the 2025 Share Incentive Plan will be regarded as a share scheme involving grant of new Shares for the purpose of Chapter 17 of the Listing Rules.

(a) Purpose

The purposes of the 2025 Share Incentive Plan are to attract and retain the best available personnel, to provide additional incentives to employees, directors and consultants of the Group and to promote the success of the value management and other incentive targets of the Company.

(b) Who May Join

The eligible participants of the 2025 Share Incentive Plan include:

(a) Directors (including the independent non-executive Directors) and employees (including full-time and part-time employees) of the Group (including persons who are granted the awards under the 2025 Share Incentive Plan as an inducement to enter into employment contracts with the Group); and

(b) persons (natural person or corporate entity) who provide services to the Group on a continuing and recurring basis in the ordinary course of business of the Group (i.e., a biopharmaceutical company) which are in the interest of the long-term growth of the Group ("**Service Provider Participants**"). Service Provider Participants include consultants or advisors who provide consultancy or advisory services to the Group in relation to research and development, production, marketing, strategic planning, finance, and administration, where the continuity and frequency of their services are akin to those of employees,

but excluding placing agents or financial advisors providing advisory services for fundraising, mergers or acquisitions, or professional service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity.

(c) Scheme Mandate Limit and Service Provider Sublimit

The Company shall not make any further grant which will result in the aggregate number of Shares underlying all Awards granted pursuant to the 2025 Share Incentive Plan (excluding any Awards lapsed in accordance with the rules of the 2025 Share Incentive Plan (the "**Scheme Rules**")) together with the Shares which may be issued under any other share schemes of the Company, to exceed 36,033,946 Shares (the "**Scheme Mandate Limit**"), representing approximately 7.0% of the total number of Shares in issue (excluding any treasury shares) as of the Adoption Date. Within the Scheme Mandate Limit, the total number of Shares which may be granted pursuant to all Awards together with the number of Shares which may be issued under any other share schemes of the Company, all of which to be granted to Service Provider Participants shall be not more than 1.0% of the total number of Shares in issue (excluding any treasury shares) as of the Adoption Date (the "**Service Provider Sublimit**"), which is equal to 5,147,706 Shares. Subject to the Scheme Mandate Limit, the 2025 Share Incentive Plan contains no provision on the maximum entitlement of each eligible participant.

(d) Exercise Period

The exercise period of the Awards granted is ten years commencing from the date upon which the Awards are deemed to be granted and accepted pursuant to the terms of the 2025 Share Incentive Plan.

(e) Vesting Period

Unless otherwise determined by the Board and/or the administrator, the Awards to be granted under the 2025 Share Incentive Plan shall vest in four (4) equal instalments of 25% each on the first, second, third and fourth anniversary of the date of grant, respectively. In any event, the vesting of the Awards shall not be less than 12 months. However, to ensure the practicability in fully attaining the purpose of the 2025 Share Incentive Plan, Awards granted to employee participants may be subject to a shorter vesting period (i.e. less than 12 months) under specific circumstances as specified in the 2025 Share Incentive Plan.

(f) Exercise or Purchase Price

For awards, the purchase price of the Awards shall be such price as determined by the Board or the administrator, at its sole and absolute discretion, on an individual basis and notified to the Grantee in the award letter. For the avoidance of doubt, the Board or the administrator may determine the purchase price to be nil.

For options, the Board or the administrator shall determine and notify the Grantee in the award letter: (a) the exercise price for such Options, provided that the exercise price shall in any event be no less than the higher of: (i) the closing price of the Shares as stated in the daily quotations sheet issued by the Stock Exchange on the date of grant; and (ii) the average closing price of the Shares as stated in the daily quotations sheets issued by the Stock Exchange for the five (5) Business Days immediately preceding the date of grant.

Subject to applicable laws, the consideration to be paid on application or acceptance of an Award and the period within which any such payments must or may be made or loans for such purposes must be repaid, shall be determined by the Board or the administrator at its sole and absolute discretion.

(g) Term of Plan and Remaining life

The 2025 Share Incentive Plan shall continue in effect after the date of adoption, until the earlier to occur: (i) the expiry of the period of ten years commencing on the Adoption Date and ending on the tenth anniversary of the Adoption Date; (ii) an ordinary resolution in general meeting passed by the Shareholders; or (iii) such date of early termination as determined by the Board. The remaining life of the 2025 Share Incentive Plan was approximately nine years and ten months as of the date of this report.

(h) Performance Targets

The Board or the administrator may, in respect of each Award and subject to all applicable laws, rules and regulations, determine such performance targets or other criteria or conditions for vesting of Awards in its sole and absolute discretion and on a case-by-case basis. Such performance targets, criteria or conditions shall be set out in the award letter. The Board or the administrator shall not set any performance targets, criteria or conditions in the award letter in respect of Awards granted to any independent non-executive Director. The performance targets refer to any performance measures, or derivations of such performance measures that may be related to the individual eligible participant approved for participation in the 2025 Share Incentive Plan and who has been granted any Award ("**Grantee**") or the Group as a whole, or to a subsidiary, division, department, region, function or business unit of the Company or the relevant service provider. The performance criteria established by the Board or the administrator may be based on any one of, or combination of, the following: (i) indicators that reflect the company value management, (ii) operating margin, (iii) gross margin, (iv) return on equity, (v) return on assets, (vi) return on investment, (vii) operating income, (viii) net operating income, (ix) pre-tax profit, (x) cash flow, (xi) revenue, (xii) expenses, (xiii) earnings before interest, taxes and depreciation, (xiv) economic value-added, (xv) market share, and (xvi) the research and development progress of the clinical trial of the Company's product. Partial achievement of the specified criteria may result in a payment or vesting corresponding to the degree of achievement as specified in the award letter. For the avoidance of doubt, an Award shall not be subject to any performance targets, criteria or conditions if none are set out in the relevant award letter.

Since the Adoption Date, no Awards were granted under the 2025 Share Incentive Plan. The number of Awards available for grant under the 2025 Share Incentive Plan as of January 1, 2025, June 27, 2025 (i.e., the adoption date) and June 30, 2025 was nil, 36,033,946 and 36,033,946, respectively.

D. Disclosure under Rule 17.07(3) of the Listing Rules

Given that all the Shares underlying the outstanding Awards granted under the 2020 Share Incentive Plan, 2023 Share Incentive Plan and 2025 Share Incentive Plan have been allotted and issued to the 2020 ESOP Platform, the 2023 ESOP Platform or the 2025 ESOP Platform, respectively, no further Share may be issued by the Company in respect of any options or awards granted under all the share schemes of the Company during the six months ended June 30, 2025. As such, the disclosure requirement under Rule 17.07(3) of the Listing Rules is not applicable.

INDEPENDENT REVIEW REPORT

Moore CPA Limited
1001-1010, North Tower, World Finance Centre,
Harbour City, 19 Canton Road,
Tsim Sha Tsui, Kowloon, Hong Kong

大華馬施雲會計師事務所有限公司
香港九龍尖沙咀廣東道19號
海港城環球金融中心北座1001-1010室

T +852 2375 3180
F +852 2375 3828

www.moore.hk

To The Board of Directors of HighTide Therapeutics, Inc.
(Incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of HighTide Therapeutics, Inc. (the "**Company**") and its subsidiaries (collectively referred to as the "**Group**") set out on pages 45 to 63, which comprise the condensed consolidated statement of financial position of HighTide Therapeutics, Inc. (the "**Company**") and its subsidiaries (the "**Group**") as at 30 June 2025, and the condensed consolidated statements of profit or loss, condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six months period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 Interim Financial Reporting ("**IAS 34**") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion soley to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

INDEPENDENT REVIEW REPORT

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

OTHER MATTER

The comparative condensed consolidated statement of profit or loss, condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six months ended 30 June 2024 and the relevant explanatory information included in these condensed consolidated financial statements were extracted from the interim financial information of the Group for the six months ended 30 June 2024 reviewed by another auditor who expressed an unmodified conclusion on the interim financial information on 28 August 2024.

Moore CPA Limited
Certified Public Accountants

Hung Wan Fong Joanne
Practising Certificate Number: P05419

Hong Kong, 25 August 2025

Condensed Consolidated Statement of Profit or Loss

For the six months ended 30 June 2025

	Notes	Six months ended 30 June	
		2025	2024
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Other income	6	**10,542**	35,089
Other gains and losses, -net	6	**5,222**	3,013
Research and development costs		**(106,414)**	(201,974)
Administrative expenses		**(21,625)**	(46,054)
Finance costs		**(1,576)**	(481)
Loss before income tax	7	**(113,851)**	(210,407)
Income tax expenses	8	**(6)**	(538)
Loss for the period		**(113,857)**	(210,945)
Attributable to:			
Owners of the parent		**(120,317)**	(210,945)
Non-controlling interests		**6,460**	–
Loss per share attributable to ordinary equity holders of the parent	10		
Basic and diluted			
For loss for the period (RMB per share)		**(0.27)**	(0.47)

Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2025

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(113,857)**	(210,945)
Other comprehensive expense		
Other comprehensive expense that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of the financial statements of subsidiaries	**(1,553)**	(1,317)
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of the financial statements of the Company	**63**	4,114
Other comprehensive (expense)/income for the period, net of tax	**(1,490)**	2,797
Total comprehensive expense for the period	**(115,347)**	(208,148)
Attributable to:		
Owners of the parent	**(121,782)**	(208,148)
Non-controlling interests	**6,435**	–

Condensed Consolidated Statement of Financial Position

As at 30 June 2025

	Notes	30 June 2025 *RMB'000* (Unaudited)	31 December 2024 *RMB'000* (Audited)
Non-current assets			
Property, plant and equipment	11	**4,496**	5,270
Right-of-use assets		**16,180**	18,621
Rental deposits		**1,580**	1,580
Long-term bank deposit		**–**	21,089
Total non-current assets		**22,256**	46,560
Current assets			
Prepayments, other receivables and other assets		**38,656**	22,284
Income tax recoverable		**557**	565
Financial assets at fair value through profit or loss ("**FVTPL**")	12	**230,062**	179,772
Long-term bank deposit matures within one year		**21,438**	–
Cash and bank balances		**215,506**	310,750
Total current assets		**506,219**	513,371
Current liabilities			
Trade payables	13	**54,846**	51,473
Other payables and accruals		**6,070**	6,054
Interest-bearing bank borrowings	14	**80,344**	46,934
Lease liabilities		**6,077**	5,485
Total current liabilities		**147,337**	109,946
Net current assets		**358,882**	403,425
Total assets less current liabilities		**381,138**	449,985

Condensed Consolidated Statement of Financial Position

As at 30 June 2025

	Notes	30 June 2025 *RMB'000* (Unaudited)	31 December 2024 *RMB'000* (Audited)
Non-current liabilities			
Lease liabilities		**13,053**	15,531
Interest-bearing bank borrowings	14	**–**	9,955
Deferred income		**272**	331
Total non-current liabilities		**13,325**	25,817
Net assets		**367,813**	424,168
Equity			
Equity attributable to owners of the parent			
Share capital	15	**364**	364
Treasury shares	15	**(44)**	(44)
Other reserves		**315,188**	423,848
Equity attributable to owners of the parent		**315,508**	424,168
Non-controlling-interests		**52,305**	–
Total equity		**367,813**	424,168

Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2025

	Attributable to owners of the parent								
	Share capital *RMB'000*	Treasury shares *RMB'000*	Premium on ordinary shares* *RMB'000*	Share option reserve* *RMB'000*	Exchange fluctuation reserve* *RMB'000*	Accumulated losses* *RMB'000*	Total equity *RMB'000*	Non-controlling interest *RMB'000*	Total equity *RMB'000*
At 31 December 2024 (audited)	364	(44)	2,315,599	223,458	(37,110)	(2,078,099)	424,168	–	424,168
(Loss)/profit for the period	–	–	–	–	–	(120,317)	(120,317)	6,460	(113,857)
Other comprehensive expense for the period	–	–	–	–	(1,465)	–	(1,465)	(25)	(1,490)
Total comprehensive (expense)/income for the period	–	–	–	–	(1,465)	(120,317)	(121,782)	6,435	(115,347)
Placing of new shares by a Structured Entity	–	–	–	–	–	–	–	45,870	45,870
Equity-settled share option arrangements	–	–	–	13,122	–	–	13,122	–	13,122
At 30 June 2025 (unaudited)	364	(44)	2,315,599	236,580	(38,575)	(2,198,416)	315,508	52,305	367,813

	Attributable to owners of the parent						
	Share capital *RMB'000*	Treasury shares *RMB'000*	Premium on ordinary shares* *RMB'000*	Share option reserve* *RMB'000*	Exchange fluctuation reserve* *RMB'000*	Accumulated losses* *RMB'000*	Total equity *RMB'000*
At 1 January 2024 (audited)	364	(44)	2,315,599	126,526	(43,360)	(1,696,311)	702,774
Loss for the period	–	–	–	–	–	(210,945)	(210,945)
Other comprehensive income for the period	–	–	–	–	2,797	–	2,797
Total comprehensive income/(expense) for the period	–	–	–	–	2,797	(210,945)	(208,148)
Equity-settled share option arrangements	–	–	–	54,036	–	–	54,036
At 30 June 2024 (unaudited)	364	(44)	2,315,599	180,562	(40,563)	(1,907,256)	548,662

* These reserve accounts comprise the consolidated reserves of approximately RMB315,188,000 and approximately RMB548,342,000 in the consolidated statements of financial position as at 30 June 2025 and 30 June 2024, respectively.

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2025

	Notes	Six months ended 30 June 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cash flows from operating activities			
Loss before tax		**(113,851)**	(210,407)
Adjustments for:			
Finance costs		**1,576**	481
Depreciation of property, plant and equipment	7	**756**	438
Depreciation of right-of-use assets	7	**2,441**	2,447
Equity-settled share option arrangements		**13,122**	54,036
Bank interest income	6	**(403)**	(2,465)
Investment income from short-term time deposits	6	**(3,812)**	(7,961)
Investment income from long-term time deposits	6	**(349)**	–
Fair value gain on financial assets at FVTPL	6	**(5,819)**	(137)
Amortisation of government grants income		**(59)**	(1,598)
Other investment income from financial assets at FVTPL	6	**(1,002)**	(420)
Loss on disposal of items of property, plant and equipment	6	**39**	171
Foreign exchange differences, net	6	**558**	(3,047)
Operating loss before changes in working capital		**(106,803)**	(168,462)
Increase in other non-current assets		**–**	(2,694)
(Increase)/decrease in prepayments, other receivables and other assets		**(16,372)**	12,119
Increase in trade payables		**3,373**	8,240
Increase/(decrease) in other payables and accruals		**16**	(32,118)
Cash used in operations		**(119,786)**	(182,915)
Income tax refund/(paid)		**2**	(592)
Net cash flows used in operating activities		**(119,784)**	(183,507)

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2025

	Notes	Six months ended 30 June 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cash flows from investing activities			
Proceeds from disposal of items of property, plant and equipment		**35**	123
Purchases of items of property, plant and equipment	11	**(56)**	(51)
Placement of bank deposits over three months		**(23,004)**	(100,202)
Purchase of financial assets at FVTPL		**(45,157)**	(42,891)
Bank interest received		**403**	2,465
Receipts of investment income from short-term time deposits		**3,812**	7,961
Receipts of investment income from long-term bank deposit		**349**	–
Receipts of investment income from financial assets at FVTPL	6	**1,002**	420
Net cash flows used in investing activities		**(62,616)**	(132,175)
Cash flows from financing activities			
New bank loans		**43,168**	–
Repayment of bank loans		**(19,713)**	(3,500)
Principal portion of lease payments		**(1,886)**	(1,828)
Interest paid		**(1,576)**	(23)
Placing of new shares by a Structured Entity		**45,870**	–
Listing expenses paid		**–**	(299)
Net cash flows generated from/(used in) financing activities		**65,863**	(5,650)
Net decrease in cash and cash equivalents		**(116,537)**	(321,332)
Cash and cash equivalents at beginning of period		**310,750**	608,212
Effect of foreign exchange rate changes, net		**(1,711)**	5,313
Cash and cash equivalents at end of period		**192,502**	292,193
Analysis of balances of cash and cash equivalents			
Cash and bank balances		**215,506**	392,395
Bank deposits over three months		**(23,004)**	(100,202)
Cash and cash equivalents as stated in the consolidated statements of cash flows		**192,502**	292,193

1. GENERAL INFORMATION

HighTide Therapeutics, Inc. (the "**Company**") was established in the Cayman Islands on 28 February 2018 by Great Mantra Group Limited and its registered address is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands, and the address of principal place of business is 40/F, Dah Sing Financial Centre No. 248 Queen's Road East Wanchai Hong Kong.

The Company is an investment holding company. During the reporting periods, the Company and its subsidiaries (collectively referred to as the "**Group**") are involved in the research and development of pharmaceutical products. In the opinion of the directors of the Company (the "**Directors**"), the ultimate holding company of the Group is HighTide Therapeutics, Inc., a company incorporated in the Cayman Islands which is ultimately controlled by Dr. LIU Liping.

The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 22 December 2023 (the "**Listing Date**").

2. BASIS OF PREPARATION

The condensed consolidated financial statements for the six months ended 30 June 2025 has been prepared in accordance with IAS 34 *Interim Financial Reporting* as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

These condensed consolidated financial statements are presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated.

3. CHANGES IN ACCOUNTING POLICIES

Other than the additional accounting policies resulting from application of amendments to IFRS Accounting Standards, and application of certain accounting policies which become relevant to the Group in the current interim period, the accounting policies adopted in the preparation of the condensed consolidated financial statements are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024.

3. CHANGES IN ACCOUNTING POLICIES (Continued)

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to an IFRS Accounting Standard, for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2025 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IAS 21	Lack of Exchangeability

The nature and impact of the amendments to an IFRS Accounting Standard are described below:

(a) Amendments to IAS 21 specify when the entity reports foreign currency transactions in its functional currency – as an adjustment to the opening balance of retained earnings and when the entity uses a presentation currency other than its functional currency or translates the results and financial position of a foreign operation – as an adjustment to the cumulative amount of translation differences – accumulated in a separate component of equity. Since the Group has no instance where one currency cannot be exchanged for another from the date of initial application of IAS 12, the amendments did not have any impact on the financial position or performance of the Group.

Accounting policies newly applied by the Group

Non-controlling interests

Profit or loss and each item of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Non-controlling interests in subsidiaries are presented separately from the Group's equity therein, which represent present ownership interests entitling their holders to a proportionate share of net assets of the relevant subsidiaries upon liquidation.

Changes in the Group's interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's relevant components of equity and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries between the Group and the non-controlling interests according to the Group's and the non-controlling interests' proportionate interests.

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of condensed consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these condensed consolidated financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the annual consolidated financial statements for the year ended 31 December 2024.

5. OPERATING SEGMENT INFORMATION

The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment in a manner consistent with the way in which information is reported internally to the Group's senior management for purposes of resource allocation and performance assessment. Therefore, no further operating segment analysis thereof is presented.

Geographical information

During the reporting period, since almost all of the Group's non-current assets were located in Chinese Mainland, no geographical segment information is presented.

Information about major customers

No revenue was derived during the six months ended 30 June 2025 and 2024. Therefore, no information about major customer is presented.

6. OTHER INCOME AND OTHER GAINS AND LOSSES, NET

An analysis of other income and other gains and losses, net is as follows:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other income		
Government grants related to expense items*	**4,850**	23,938
Government grants related to assets**	**58**	98
Bank interest income	**403**	2,465
Investment income from long-term time deposits	**349**	–
Investment income from short-term time deposits	**3,812**	7,961
Other investment income from financial assets at FVTPL	**1,002**	420
Others	**68**	207
	10,542	35,089
Other gains and losses, -net		
Fair value gain on financial assets at FVTPL	**5,819**	137
Foreign exchange losses, net	**(558)**	3,047
Loss on disposal of items of property, plant and equipment	**(39)**	(171)
	5,222	3,013

* Government grants related to expense items mainly represent subsidies received from local governments for the purpose of compensation of expenses for research and clinical trial activities, allowance for new drug development and talent funds. The main grantor is the Development Affairs Office of Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, Futian District, Shenzhen and Hong Kong Science and Technology Parks Corporation. Government grants received for which related expenses have not yet been incurred are included in deferred income in the condensed consolidated statement of financial position.

** Grants related to assets are credited to deferred income and released to the condensed consolidated statement of profit or loss in equal annual instalments over the estimated useful lives of the related assets.

7. LOSS BEFORE INCOME TAX

The Group's loss before income tax is arrived at after charging/(crediting):

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Depreciation of property, plant and equipment	**756**	438
Depreciation of right-of-use assets	**2,441**	2,447
Other professional service fees*	**6,294**	8,905
Lease payments relating to short-term and low-value assets	**183**	922
Auditor's remuneration	**300**	700
Investment related expenses	**2,186**	1,400
Research and development costs:		
Third-party contracting expenses	**77,420**	146,294
Staff costs	**16,140**	21,056
Expenses under the employee long-term incentive plans	**9,601**	31,560
Others	**3,253**	3,064
	106,414	201,974
Employee benefit expense (including directors' and chief executive's remuneration):		
Wages and salaries	**18,610**	25,592
Pension scheme contributions (defined contribution scheme), social welfare and other welfare	**3,118**	3,286
Equity-settled share option expense	**13,122**	54,036
	34,850	82,914

* Other professional service fees mainly consisted of business consulting fees and other service fees paid to third-party professional service providers.

8. INCOME TAX EXPENSES

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, upon payments of dividends by the Company to its shareholders, no Cayman Islands withholding tax is imposed.

British Virgin Islands

Under the current laws of the British Virgin Islands ("**BVI**"), the subsidiary incorporated in the BVI is not subject to tax on income or capital gains. In addition, upon payments of dividends by the subsidiary to its shareholders, no BVI withholding tax is imposed.

Hong Kong

The subsidiary incorporated in Hong Kong is subject to income tax at the rate of 8.25% (2024: 8.25%) on the estimated assessable profits arising in Hong Kong during the year.

Chinese Mainland

No provision for Chinese Mainland income tax pursuant to the Corporate Income Tax Law of the People's Republic of China (the "**PRC**") and the respective regulations (the "**CIT Law**") has been made as the Group's subsidiaries which operate in Chinese Mainland are in loss position and have no estimated taxable profits.

Shenzhen HighTide was approved as a high technology enterprise under the relevant tax rules and regulations in December 2022 and Shenzhen HighTide is entitled a preferential income tax rate of 15% from 2022 to 2024. Since the re-evaluation is scheduled for December 2025, the qualification has not been re-evaluated as of the reporting date. According to Announcement No. 24 [2017] of the State Taxation Administration, in the year when the high technology enterprise qualification expires (i.e., 2025), the enterprise may provisionally calculate and prepay corporate income tax at a 15% rate before the re-evaluation results are announced.

JSK Consumer Healthcare Ltd, Shanghai Fusion Therapeutics Inc., Hebei Puhui Pharmaceutical Co., Ltd and Nanchang Fusion Therapeutics Inc. have met the requirement under the relevant tax rules and regulations for small and low-profit enterprises, and accordingly, were subject to a reduced preferential CIT rate of 20%, and annual taxable income was entitled to be included in the actual taxable income at reduced rates of 25% during the period (2024: 25%).

Australia

The subsidiary incorporated in Australia was subject to income tax at the rate of 25% (2024: 25%) on the estimated assessable profits arising in Australia during the period.

8. INCOME TAX EXPENSES (Continued)

USA

The subsidiary incorporated in Maryland, the USA is subject to statutory United States federal corporate income tax at a rate of 21% (2024: 21%). In addition, it is also subject to the state income tax in Maryland at a rate of 8.25% (2024: 8.25%) during the period. Other states including California, Florida and New Jersey also impose state income tax on the subsidiary to the extent that a sufficient nexus, or taxable connection, exists between the subsidiary and the respective states. The subsidiary was subject to the states income tax in California at a rate of 8.84% (2024: 8.84%), in Florida at a rate of 5.50% (2024: 5.5%) and in New Jersey at a rate of 6.50% (2024: 7.50%) during the period.

The income tax expense of the Group during the period is analysed as follows:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current tax:		
Charge for the period	**6**	162
Adjustments in respect of current tax of previous periods	**–**	376
Total tax expense for the period	**6**	538

Deferred tax assets have not been recognised in respect of unused tax losses as they have arisen in subsidiaries that have been loss-making for some time and it is not considered probable that taxable profits in foreseeable future will be available against which the tax losses can be utilised.

9. DIVIDENDS

No dividend was paid or declared by the Company during the reporting periods.

10. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent and the weighted average number of ordinary shares of 452,159,904 (30 June 2024: 452,074,904) in issue (excluding shares reserved for share incentive scheme) during the year.

No adjustment was made to the basic loss per share amounts presented for the periods ended 30 June 2025 and 2024 in respect of a dilution as the impact of the share-based payment had an anti- dilutive effect on the basic loss per share amounts presented.

10. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Continued)

The calculations of basic and diluted loss per share are based on:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to equity holders of the parent, used in the basic loss per share calculation:		
– Ordinary shares	**(120,317)**	(210,945)

	Six months ended 30 June	
	2025	2024
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of participating equity instruments in issue during the period used in the basic loss per share calculation		
– Ordinary shares	**452,159,904**	452,074,904
Loss per share (basic and diluted) (RMB per share)	**(0.27)**	(0.47)

11. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2025, the Group acquired assets at a cost of RMB56,000 (30 June 2024: RMB51,000).

Assets with a net book value of RMB74,000 were disposed of by the Group during the six months ended 30 June 2025 (30 June 2024: RMB294,000), resulting in a net loss on disposal of RMB39,000 (30 June 2024: RMB171,000).

No impairment loss was recognised during the six months ended 30 June 2025 (six months ended 30 June 2024: Nil).

12. FINANCIAL ASSETS AT FVTPL

	30 June 2025 *RMB'000* (Unaudited)	31 December 2024 *RMB'000* (audited)
Listed equity investments, at fair value	**215,334**	140,854
Treasury bills and money market funds	**14,728**	38,918
	230,062	179,772

The above equity investments were classified as financial assets at fair value through profit or loss as they were held for trading. The above equity investments were purchased through two structured entities, Apollo Multi-Asset Growth Fund and Chaince Capital Fund LP (together the "**Funds**"), that the Group invested with initial capital contribution of USD12,500,000 and USD12,500,000 respectively. During the half year ended June 30, 2025, one of the Funds, i.e. Apollo (the "**Fund**"), introduced a new investor, who is an independent third party with the Group, through placement of new shares. After the new investor acquired a stake in the Fund for USD6,400,000, the Company still held approximately 67% (12,375 shares) of the Fund's shares, while the new investor held approximately 33% of the shares. Following the completion of this placement of new shares, the Group continues to consolidate the Funds considering the Group still holds majority's equity interests in the Funds.

13. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting periods, based on the invoice date, is as follows:

	30 June 2025 *RMB'000* (Unaudited)	31 December 2024 *RMB'000* (audited)
Within one year	**54,846**	51,473
Total	**54,846**	51,473

The trade payables are non-interest-bearing and are normally settled within one month after the receipt of the invoice.

14. INTEREST-BEARING BANK BORROWINGS

	Effective interest rate (%) per annum	Maturity	RMB'000
As at 30 June 2025			
Bank loans – unsecured, repayable within one year or on demand*	**2.95%-3.70%**	**2025-2026**	**80,344**
As at 31 December 2024			
Bank loans – unsecured, repayable within one year or on demand*	3.20%-3.70%	2025	46,934
Bank loans – unsecured, repayable over one year but within two years	3.50%	2026	9,955
			56,889

* As at 30 June 2025, included in the balance is an unsecured bank loan of RMB3,500,000 which is guaranteed by Shenzhen Hi-Tech Investment & Financing Guarantee Company, an independent third party.

All bank loans are denominated in RMB.

15. SHARE CAPITAL

Issued and fully paid as at 30 June 2025 and 31 December 2024:

	Issued share capital		
	Number of shares in issue	Share capital *USD'000* (Unaudited)	RMB equivalent *RMB'000* (Unaudited)
Issued and fully paid:			
Ordinary shares of USD0.0001 each	514,770,668	51	364

1. Own equity instruments of 62,610,764 shares (31 December 2024: 62,610,764 shares) which are reacquired and held by the Company or the Group (treasury shares) are recognised directly in equity at cost.

16. RELATED PARTY TRANSACTIONS

Compensation of key management personnel of the Group:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Short term employee benefits	**6,239**	8,069
Equity-settled share option arrangements	**11,700**	45,220
Total compensation paid to key management personnel	**17,939**	53,289

17. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and bank balances, long-term bank deposit matures within one year, financial assets included in prepayments, other receivables and other assets, rental deposits, trade payables, interest-bearing bank borrowings, and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all required significant inputs to fair value of an instrument are observable, the instruments are included in Level 2. If one or more of the significant inputs are not based on observable market data, the instruments are included in Level 3.

The Group has investments in listed equities not quoted in an active markets which fair values are determined on recent transaction valuations and comparable company multipliers. The Group classifies the fair values of these investments as Level 2.

The fair values of investments in treasury bills and money market funds are based on quoted market prices.

17. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2025 (Unaudited)

	Fair value measurement using			
	Quoted prices in active markets (Level 1) *RMB'000*	Significant observable inputs (Level 2) *RMB'000*	Significant unobservable Inputs (Level 3) *RMB'000*	Total *RMB'000*
Financial assets				
Financial assets at FVTPL	**105,073**	**124,989**	**–**	**230,062**

As at 31 December 2024 (Audited)

	Fair value measurement using			
	Quoted prices in active markets (Level 1) *RMB'000*	Significant observable inputs (Level 2) *RMB'000*	Significant unobservable Inputs (Level 3) *RMB'000*	Total *RMB'000*
Financial assets				
Financial assets at FVTPL	53,022	126,750	–	179,772

There were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 during the period.

18. EVENTS AFTER THE REPORTING PERIOD

On 7 July 2025, a total of 56,555,000 Placing Shares have been successfully placed by the Placing Agents to not less than six independent placees at the Placing Price of HK$2.21 per Placing Share pursuant to the terms and conditions of the Placing Agreement on 7 July 2025. The aggregate gross proceeds from the Placing are approximately HK$125.0 million and the aggregate net proceeds from the Placing to be received by the Company (after deduction of the commissions and expenses relating to the Placing) amounted to approximately HK$123.4 million. Immediately after completion of the Placing Number of Shares is 571,325,668.

DEFINITIONS

In this report, the following expressions have the meanings set out below unless the context requires otherwise.

"2020 ESOP Platform"	Wisdom Spring Group Limited
"2020 Share Incentive Plan"	the employee long term incentive plan originally adopted by our Company on January 22, 2020, amended and restated on October 18, 2021 and further amended and restated in its entirety on March 4, 2022
"2023 ESOP Platform"	Wisdom Summer Group Limited
"2023 Share Incentive Plan"	the employee long term incentive plan adopted by our Company on May 24, 2023
"2025 Share Incentive Plan"	the share incentive plan adopted by an ordinary resolution passed by the Shareholders in the annual general meeting held on June 27, 2025
"2025 ESOP Platform"	an independent third party trustee to be appointed by the Company to hold the share awards underlying the 2025 Share Incentive Plan
"AH"	alcoholic hepatitis, a type of alcohol-associated liver disease characterized by acute liver inflammation
"AIC Group"	refers to Dr. Liu, the Founder BVI, Greaty Investment, ZT Global Energy and Orient Champion
"associate(s)"	has the meaning ascribed to it under the Listing Rules
"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of directors of our Company
"China", "Mainland China" or "PRC"	People's Republic of China, but for the purpose of this report and for geographical reference only and except where the context requires otherwise, references in this report to "China" and the "PRC" do not apply to Hong Kong, Macau and Taiwan
"cholestatic liver disease"	a disease characterized by a decrease or blockage in the flow of bile, including primary sclerosing cholangitis and primary biliary cholangitis
"clinical trial/study"	a research study for validating or finding the therapeutic effects and side effects of test drugs in order to determine the therapeutic value and safety of such drugs
"Companies Ordinance"	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) as amended, supplemented or otherwise modified from time to time

"Company" or "our Company"	HighTide Therapeutics, Inc., a company incorporated under the laws of the Cayman Islands with limited liability on February 28, 2018
"Core Product"	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this report, our Core Product refers to HTD1801
"Corporate Governance Code"	the "Corporate Governance Code" as contained in Appendix C1 to the Listing Rules
"CRO"	contract research organization, a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis
"CVDs"	cardiovascular diseases, conditions affecting the heart or blood vessels
"diabetes"	a complex, chronic metabolic disease characterized by elevated levels of blood glucose, which leads over time to serious damage to the heart, blood vessels, eyes, kidneys, nerves and other organs, comprised of two categories including type 1 diabetes mellitus and type 2 diabetes mellitus
"digestive diseases"	health conditions associated with the digestive system
"Director(s)" or "our Director(s)"	the director(s) of our Company, including all executive, non-executive and independent non-executive Directors
"Dr. Liu"	Dr. LIU Liping (劉利平), the founder, executive Director and chief executive officer of our Company
"Family Trust"	The ABLE XL FAMILY TRUST 2020, an irrevocable discretionary trust settled by Dr. Liu as the settlor pursuant to a trust deed dated December 31, 2020 under the laws of the State of Delaware for her succession planning, and pursuant to the aforesaid trust deed, the beneficiary is any one or more of Dr. Liu's children and more remote issue
"FDA"	the United States Food and Drug Administration
"Founder BVI"	GREAT MANTRA GROUP LIMITED, a limited company incorporated in the BVI on November 24, 2017, one of the members of the AIC Group and wholly-owned by the Family Trust
"FTD"	fast track designation, a designation granted by the FDA of a drug for expedited review to facilitate the development of drugs which treat serious or life-threatening condition or fill an unmet medical need

DEFINITIONS

"Group" or "our Group"	our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)
"Hepalink"	Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (深圳市海普瑞藥業集團股份有限公司), a joint stock limited company incorporated under the laws of the PRC, whose A shares are listed on the Shenzhen Stock Exchange (stock code: 002399) and H Shares are listed on the Stock Exchange (stock code: 9989)
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"IBD"	inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine, comprised of two major categories including Crohn's disease (a type of inflammatory bowel disease which can affect any part of the gastrointestinal tract) and ulcerative colitis
"Listing"	the listing of our Shares on the Main Board
"Listing Date"	December 22, 2023, the date on which dealings in the Shares first commence on the Main Board
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"MASH"	metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis or NASH), an advanced form of MASLD
"MASLD"	metabolic dysfunction-associated steatotic liver disease (formerly known as nonalcoholic fatty liver disease or NAFLD), characterized by the excessive fat accumulation in the liver. At EASL Congress 2023, the multinational liver societies leaders from La Asociación Latinoamericana para el Estudio del Hígado (ALEH), American Association for the Study of Liver Diseases (AASLD), and European Association for the Study of the Liver (EASL) as well as the co-chairs of the MASLD Nomenclature Initiative announced that steatotic liver disease (SLD) was chosen as an overarching term to encompass the various aetiologies of steatosis

"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"MRI-PDFF"	magnetic resonance imaging-derived proton density fat fraction, a noninvasive, quantitative, and accurate measure of liver fat content
"NMPA"	National Medical Products Administration (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局) from 2013 to 2018 and the State Food and Drug Administration (國家食品藥品監督管理局) from 2003 to 2013
"obesity"	abnormal or excessive fat accumulation in the body; defined as an individual having a body mass index over 30 kg/m^2 or more
"ODD"	orphan drug designation, a designation granted by the FDA to a drug or biological product which prevents, diagnoses or treats a rare disease or condition, qualifying the sponsors for certain incentives
"Phase I clinical trial"	a study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its efficacy
"Phase II clinical trial"	a study in which a drug is administered to a limited patient population to preliminarily evaluate the efficacy of the product for specific targeted diseases, to identify possible adverse effects and safety risks, and to determine optimal dosage
"placebo"	a medical treatment or preparation with no specific pharmacological activity
"pre-diabetes"	a condition characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes
"Pre-IPO Share Incentive Plans"	the 2020 Share Incentive Plan and the 2023 Share Incentive Plan, collectively
"primary endpoint"	the specific key measurement upon which a clinical study is designed to assess the effect of the drugs being investigated
"Prospectus"	the prospectus of the Company dated December 14, 2023
"PSC"	primary sclerosing cholangitis, a life-threatening, multifactorial and rare liver disease characterized by hepatic inflammation, scarring and abnormal liver damage

DEFINITIONS

"R&D"	research and development
"Remuneration Committee"	the remuneration committee of the Board
"Reporting Period"	the six months ended June 30, 2025
"RMB"	the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
"Shareholder(s)"	holder(s) of our Share(s)
"Share(s)" or "Ordinary Share(s)"	ordinary share(s) in the share capital of our Company with a par value of US$0.0001 each
"SHTG"	severe hypertriglyceridemia, SHTG is the presence of high levels of triglycerides, a type of fat, in the blood. SHTG is well known to be associated with other complex and serious disorders such as acute pancreatitis and CVDs
"Stock Exchange"	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchange and Clearing Limited
"subsidiary(ies)"	has the meaning ascribed to it in Section 15 of the Companies Ordinance
"substantial shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"T2DM"	type 2 diabetes mellitus, a form of diabetes characterized by high blood sugar, insulin resistance and relative lack of insulin
"TG"	triglycerides, the main constituents of body fat in humans
"US$"	United States dollars, the lawful currency of the United States
"we", "us" or "our"	the Company or the Group, as the context requires